# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001104659-25-061154
**Filing Date:** 2025-6
**Character Count:** 141115
**Document Hash:** e58a7004fe1b1815ddb637c6fc31b7e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-061154.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001104659-25-061154

**CONFORMED SUBMISSION TYPE**: 11-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20241231

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 11-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 251061351

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **WASHINGTON, D. C. 20549**

**FORM 11-K**

**FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS<br> AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

(Mark One)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;⌧ **ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the fiscal year ended December 31, 2024

**OR**

---

| | |
|:---|:---|
| ◻ | **TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

For the transition period from ____________________ to _____________________

Commission File Number 1-2189

A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

**FINANCIAL STATEMENTS AND** 

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

**ABBOTT LABORATORIES STOCK RETIREMENT PLAN** 

**DECEMBER 31, 2024 AND 2023**

**C O N T E N T S**

---

| | |
|:---|:---|
|  | **Page** |
| [REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM](#he_01) | [3](#he_01) |
| FINANCIAL STATEMENTS |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS](#he_02) | [5](#he_02) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS](#he_03) | [6](#he_03) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[NOTES TO FINANCIAL STATEMENTS](#he_04) | [7](#he_04) |
| [SUPPLEMENTAL SCHEDULE](#he_006) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)](#he_005) | [19](#he_005) |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan

**Opinion on the financial statements**

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the "Plan") as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

**Basis for opinion**

These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Supplemental information**

The schedule of assets (held at end of year) as of December 31, 2024 ("supplemental information") has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan's auditor since 2002.

Chicago, Illinois

June 20, 2025

---

| | | |
|:---|:---|:---|
| **Abbott Laboratories Stock Retirement Plan** | | |
| **STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS** | **STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS** | |
| **December 31, 2024 and 2023** | | |
| **(Dollars in thousands)** | | |
|  | 2024 | 2023 |
| Assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $1011 | $81 |
| &nbsp;&nbsp;&nbsp;Investments, at fair value | 15576603 | 14271803 |
| &nbsp;&nbsp;&nbsp;Employer contributions receivable | 43461 | 5524 |
| &nbsp;&nbsp;&nbsp;Notes receivable from participants | 100167 | 94074 |
| &nbsp;&nbsp;&nbsp;Accrued interest and dividend income | 4000 | 2994 |
| &nbsp;&nbsp;&nbsp;Due from brokers | 30426 | 121715 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | 15755668 | 14496191 |
| Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Investments sold short, at fair value | 19750 | 116452 |
| &nbsp;&nbsp;&nbsp;Accrued investment expenses | 208 | 301 |
| &nbsp;&nbsp;&nbsp;Due to brokers | 10441 | 159 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 30399 | 116912 |
| **NET ASSETS AVAILABLE FOR BENEFITS** | $15725269 | $14379279 |

---

The accompanying notes are an integral part of these statements.

---

| |
|:---|
| **Abbott Laboratories Stock Retirement Plan** |
| **STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS** |
| **Year ended December 31, 2024** |
| **(Dollars in thousands)<br>**  |

---

---

| | |
|:---|:---|
| Additions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contributions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employer | $244939 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participant | 412674 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rollovers | 41699 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total contributions | 699312 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment income |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net appreciation in fair value of investments | 1800685 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest and dividends | 138037 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 1938722 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income on notes receivable from participants | 6018 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total additions | 2644052 |
| Deductions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefits paid to participants | 1297841 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expenses | 221 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deductions | 1298062 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET INCREASE** | 1345990 |
| Net assets available for benefits |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning of year | 14379279 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End of year | $15725269 |

---

The accompanying notes are an integral part of this statement.

**Abbott Laboratories Stock Retirement Plan** 

**NOTES TO FINANCIAL STATEMENTS**

**December 31, 2024 and 2023**

**NOTE A - DESCRIPTION OF THE PLAN**

The following description of the Abbott Laboratories Stock Retirement Plan (the "Plan") provides only general information. Participants should refer to the Plan document for a more complete description of the Plan's provisions.

***General***

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the "IRC"), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA").

In general, United States employees of Abbott Laboratories ("Abbott") and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure ("Abbott Green" employees).

Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company ("Custodian" or "Trustee") serves as the Plan's custodian and trustee.

***Contributions and Vesting***

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust ("Trust"). The Trust is administered by the Trustee and an investment committee (the "Committee").

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% and effective January 1, 2024 up to 50% (previously capped at 25%) of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employee's eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2024 was 5% of the participant's eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

**Abbott Laboratories Stock Retirement Plan** 

**NOTES TO FINANCIAL STATEMENTS - CONTINUED** 

**December 31, 2024 and 2023**

**NOTE A - DESCRIPTION OF THE PLAN - Continued**

***Contributions and Vesting - Continued***

Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Effective June 1, 2024, Plan participants who are not actively participating in the Abbott Laboratories Annuity Retirement Plan may receive an annual employer contribution equal to 3% of the participant's eligible earnings, regardless of whether the participant contributes to the Plan. The 3% annual employer contribution will be made shortly after the end of the Plan year only to the eligible participants who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or who have terminated from employment during that Plan year due to death or qualifying retirement or disability during such Plan year.

Employer contributions are invested according to the participant's investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan's default investment option.

**Abbott Laboratories Stock Retirement Plan** 

**NOTES TO FINANCIAL STATEMENTS - CONTINUED** 

**December 31, 2024 and 2023**

**NOTE A - DESCRIPTION OF THE PLAN - Continued**

***Contributions and Vesting – Continued***

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

---

| | |
|:---|:---|
|  | Vesting |
| Service | percentage |
| Less than two years | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% |
| Two years or more | 100% |

---

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65. Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee's termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2024, forfeitures reduced Abbott's employer contributions by approximately $5.1 million. Approximately $1.0 million and $1.0 million in forfeitures were available at the end of 2024 and 2023, respectively.

***Distributions and In-Service Withdrawals***

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1st of April following the year the participant reaches age 73 or, if earlier, the 31st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

**Abbott Laboratories Stock Retirement Plan** 

**NOTES TO FINANCIAL STATEMENTS - CONTINUED** 

**December 31, 2024 and 2023**

**NOTE A - DESCRIPTION OF THE PLAN - Continued**

***Distributions and In-Service Withdrawals - Continued***

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant's account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

***Notes Receivable from Participants***

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee's anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee's anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

**Abbott Laboratories Stock Retirement Plan** 

**NOTES TO FINANCIAL STATEMENTS - CONTINUED** 

**December 31, 2024 and 2023**

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Accounting***

The financial statements have been prepared using the accrual basis of accounting.

***Use of Estimates***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation***

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

<u>Common stock, mutual funds, real estate investment trusts ("REITs") and futures contracts</u> - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

<u>Collective trust funds and Private 40-Act mutual funds</u> - Valued at the net asset value ("NAV") provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

<u>Corporate debt, government debt and other</u> - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region's market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond's terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

*<u>Futures contracts</u>*

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2024 and 2023, the Plan held futures contracts with a notional amount of approximately $629,000 and $803,000, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2024 and 2023. Changes in fair value are accounted for as investment income (loss) within net appreciation in fair value of investments and totaled approximately $43,000 for the year ended December 31, 2024.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation - Continued***

*<u>Short sales</u>*

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2024 and 2023 (dollars in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2024** | Quoted <br> Prices in <br> Active <br> Markets | Significant <br> Other<br> Observable<br> Inputs | Significant<br> Unobservable<br> Inputs | Measured at<br> NAV | Total |
| Assets - Investments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common stock | $5066260 | $- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $- | $5066260 |
| &nbsp;&nbsp;&nbsp;Mutual funds | 108326 |  |  |  | 108326 |
| &nbsp;&nbsp;&nbsp;REITs | 25888 |  |  |  | 25888 |
| &nbsp;&nbsp;&nbsp;Collective trust funds |  |  |  | 9592890 | 9592890 |
| &nbsp;&nbsp;&nbsp;Corporate debt |  | 235392 |  |  | 235392 |
| &nbsp;&nbsp;&nbsp;Government debt |  | 154812 |  |  | 154812 |
| &nbsp;&nbsp;&nbsp;Private 40-Act mutual funds | - | - | - | 393035 | 393035 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments, at fair value | $5200474 | $390204 | $- | $9985925 | $15576603 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2024** | Quoted <br> Prices in<br> Active<br> Markets | Significant<br> Other <br> Observable<br> Inputs | Significant<br> Unobservable<br> Inputs | Measured at<br> NAV | Total |
| Liabilities - Investments sold short: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Government debt | $- | $19750 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $19750 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments sold short, at fair value | $- | $19750 | $- | $- | $19750 |

---

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation - Continued***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2023** | Quoted <br> Prices in <br> Active <br> Markets | Significant<br> Other <br> Observable <br> Inputs | Significant<br> Unobservable <br> Inputs | Measured at<br> NAV | Total |
| Assets - Investments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common stock | $5071247 | $- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $- | $5071247 |
| &nbsp;&nbsp;&nbsp;Mutual funds | 112479 |  |  |  | 112479 |
| &nbsp;&nbsp;&nbsp;REITs | 25697 |  |  |  | 25697 |
| &nbsp;&nbsp;&nbsp;Collective trust funds |  |  |  | 8074869 | 8074869 |
| &nbsp;&nbsp;&nbsp;Corporate debt |  | 269066 |  |  | 269066 |
| &nbsp;&nbsp;&nbsp;Government debt |  | 32173 |  |  | 32173 |
| &nbsp;&nbsp;&nbsp;Private 40-Act mutual funds |  |  |  | 676472 | 676472 |
| &nbsp;&nbsp;&nbsp;Other | - | 9800 | - | - | 9800 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments, at fair value | $5209423 | $311039 | $- | $8751341 | $14271803 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2023** | Quoted <br> Prices in <br> Active <br> Markets | Significant<br> Other <br> Observable <br> Inputs | Significant<br> Unobservable <br> Inputs | Measured at<br> NAV | Total |
| Liabilities - Investments sold short: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Government debt | $- | $116452 | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $116452 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments sold short, at fair value | $- | $116452 | $- | $- | $116452 |

---

Participants are permitted to make redemptions from the Plan's investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2024 and 2023. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation - Continued***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | 2024 | 2024 | 2024 | 2024 |
|  | Fair value<br> (NAV) | Redemption<br> frequency | Redemption<br> notice period | Restrictions |
| Funds filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Collective trusts | $9592890 | Daily | 0 - 5 days |  |
| Funds not filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Private 40-Act mutual funds |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term fixed income | 393035 | Daily |  | Yes (a) |
|  | $9985925 |  |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | 2023 | 2023 | 2023 | 2023 |
|  | Fair value<br> (NAV) | Redemption<br> frequency | Redemption<br> notice period | Restrictions |
| Funds filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Collective trusts | $8074869 | Daily | 0 - 5 days |  |
| Funds not filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Private 40-Act mutual funds |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities | 29900 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate fixed income | 55771 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inflation-indexed bonds | 8031 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International fixed income | 22751 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-related securities | 30103 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal fixed income | 2573 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term fixed income | 486796 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Government securities | 40547 | Daily |  | Yes (a) |
|  | 676472 |  |  |  |
|  | $8751341 |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or
1% of the respective fund's net assets during any 90-day period for any one shareholder. In consideration of the best interests
of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount
in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares
would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request,
but may take up to seven days.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Notes Receivable from Participants***

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

***Income Recognition***

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

***Contributions***

Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation. Freedom 2 Save employer contributions, true-up employer matching contributions, and the 3% annual employer contribution are accrued in the year in which they are earned.

***Administrative Expenses***

Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie stock, which are included in net appreciation in fair value of investments. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. Abbott pays other recordkeeping and administration fees, where applicable. Expenses that are paid by Abbott are excluded from these financial statements.

***Payment of Benefits***

Benefits are recorded when paid.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE C - INVESTMENTS**

Distributions of Abbott common shares and conversions of participants' common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2024 and 2023 is presented below:

---

| | | |
|:---|:---|:---|
|  | 2024 | 2023 |
| Abbott common shares, 24,199,951 and 26,051,349 shares, respectively (dollars in thousands) | $2737256 | $2867472 |
| Market value per share | $113.11 | $110.07 |

---

**NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS**

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee's common stock. A significant portion of the Plan's assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2024, the Plan received $55.8 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

**NOTE E - PLAN TERMINATION**

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants' account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant's share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

**Abbott Laboratories Stock Retirement Plan**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE F - TAX STATUS**

The Internal Revenue Service ("IRS") has determined and informed Abbott by a letter dated April 13, 2022, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

**NOTE G - RISKS AND UNCERTAINTIES**

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

**NOTE H - SUBSEQUENT EVENTS**

Management of the Plan has evaluated subsequent events from December 31, 2024 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

Effective January 1, 2025, forfeitures will be used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

SUPPLEMENTAL SCHEDULE

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - employer securities** |  |  |  |
| &nbsp;&nbsp;\* | &nbsp;&nbsp;&nbsp;ABBOTT LABORATORIES, common shares |  |  | $2737256 |
|  | **Common stock** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;10X GENOMICS INC CL A |  |  | 16 |
|  | &nbsp;&nbsp;&nbsp;5TH 3RD BANCORP COM |  |  | 940 |
|  | &nbsp;&nbsp;&nbsp;ABBVIE INC. |  |  | 2068558 |
|  | &nbsp;&nbsp;&nbsp;ACADIA HEALTHCARE CO INC COM |  |  | 119 |
|  | &nbsp;&nbsp;&nbsp;ACUITY BRANDS INC COM |  |  | 296 |
|  | &nbsp;&nbsp;&nbsp;ADT INC DEL COM |  |  | 75 |
|  | &nbsp;&nbsp;&nbsp;ADVANCE AUTO PTS INC COM |  |  | 92 |
|  | &nbsp;&nbsp;&nbsp;ADVANCED DRAIN SYS INC DEL COM |  |  | 166 |
|  | &nbsp;&nbsp;&nbsp;AECOM |  |  | 470 |
|  | &nbsp;&nbsp;&nbsp;AES CORP COM |  |  | 300 |
|  | &nbsp;&nbsp;&nbsp;AFFILIATED MANAGERS GROUP INC COM STK |  |  | 178 |
|  | &nbsp;&nbsp;&nbsp;AFFIRM HLDGS INC CL A |  |  | 519 |
|  | &nbsp;&nbsp;&nbsp;AFLAC INC COM |  |  | 1899 |
|  | &nbsp;&nbsp;&nbsp;AGCO CORP COM |  |  | 191 |
|  | &nbsp;&nbsp;&nbsp;AGILENT TECHNOLOGIES INC COM |  |  | 1269 |
|  | &nbsp;&nbsp;&nbsp;AIR LEASE CORP CL A |  |  | 165 |
|  | &nbsp;&nbsp;&nbsp;AKAMAI TECHNOLOGIES INC COM STK |  |  | 468 |
|  | &nbsp;&nbsp;&nbsp;ALASKA AIR GROUP INC COM |  |  | 267 |
|  | &nbsp;&nbsp;&nbsp;ALBEMARLE CORP COM |  |  | 332 |
|  | &nbsp;&nbsp;&nbsp;ALBERTSONS COS INC CL A |  |  | 270 |
|  | &nbsp;&nbsp;&nbsp;ALIGN TECHNOLOGY INC COM |  |  | 213 |
|  | &nbsp;&nbsp;&nbsp;ALLEGION PLC COMMON STOCK |  |  | 376 |
|  | &nbsp;&nbsp;&nbsp;ALLEGRO MICROSYSTEMS INC DEL COM |  |  | 88 |
|  | &nbsp;&nbsp;&nbsp;ALLIANT ENERGY CORP COM |  |  | 498 |
|  | &nbsp;&nbsp;&nbsp;ALLISON TRANSMISSION HOLDING |  |  | 307 |
|  | &nbsp;&nbsp;&nbsp;ALLSTATE CORP COM |  |  | 1406 |
|  | &nbsp;&nbsp;&nbsp;ALLY FINL INC COM |  |  | 281 |
|  | &nbsp;&nbsp;&nbsp;ALNYLAM PHARMACEUTICALS INC COM |  |  | 112 |
|  | &nbsp;&nbsp;&nbsp;AMCOR PLC |  |  | 445 |
|  | &nbsp;&nbsp;&nbsp;AMDOCS |  |  | 313 |
|  | &nbsp;&nbsp;&nbsp;AMEDISYS INC COM |  |  | 95 |
|  | &nbsp;&nbsp;&nbsp;AMENTUM HLDGS INC COM |  |  | 90 |
|  | &nbsp;&nbsp;&nbsp;AMER FINL GROUP INC OH COM STK |  |  | 323 |
|  | &nbsp;&nbsp;&nbsp;AMER SPORTS INC COM |  |  | 53 |
|  | &nbsp;&nbsp;&nbsp;AMEREN CORP COM |  |  | 781 |
|  | &nbsp;&nbsp;&nbsp;AMERICAN AIRLINES INC COM |  |  | 348 |
|  | &nbsp;&nbsp;&nbsp;AMERICAN WTR WKS CO INC NEW COM |  |  | 799 |
|  | &nbsp;&nbsp;&nbsp;AMERIPRISE FINL INC COM |  |  | 150 |
|  | &nbsp;&nbsp;&nbsp;AMETEK INC NEW COM |  |  | 1369 |
|  | &nbsp;&nbsp;&nbsp;AMKOR TECHNOLOGY INC COM |  |  | 95 |
|  | &nbsp;&nbsp;&nbsp;ANSYS INC COM |  |  | 968 |
|  | &nbsp;&nbsp;&nbsp;ANTERO MIDSTREAM CORPORATION |  |  | 103 |
|  | &nbsp;&nbsp;&nbsp;ANTERO RES CORP COM |  |  | 334 |
|  | &nbsp;&nbsp;&nbsp;APA CORP COM |  |  | 275 |
|  | &nbsp;&nbsp;&nbsp;API GROUP CORPORATION COM |  |  | 269 |
|  | &nbsp;&nbsp;&nbsp;APTARGROUP INC COM |  |  | 340 |
|  | &nbsp;&nbsp;&nbsp;APTIV PLC NEW ORD |  |  | 467 |
|  | &nbsp;&nbsp;&nbsp;ARAMARK COM |  |  | 321 |
|  | &nbsp;&nbsp;&nbsp;ARCH CAPITAL GROUP COM STK |  |  | 1096 |
|  | &nbsp;&nbsp;&nbsp;ARCHER-DANIELS-MIDLAND CO COM |  |  | 793 |
|  | &nbsp;&nbsp;&nbsp;ARMSTRONG WORLD INDS INC NEW COM STK |  |  | 134 |
|  | &nbsp;&nbsp;&nbsp;ARROW ELECTR INC COM |  |  | 195 |
|  | &nbsp;&nbsp;&nbsp;ASHLAND INC COM |  |  | 114 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;ASPEN |  |  | 220 |
|  | &nbsp;&nbsp;&nbsp;ASSURANT INC COM |  |  | 365 |
|  | &nbsp;&nbsp;&nbsp;ASSURED GUARANTY LTD COMMON STK |  |  | 149 |
|  | &nbsp;&nbsp;&nbsp;ASTERA LABS INC COM |  |  | 447 |
|  | &nbsp;&nbsp;&nbsp;ATI INC COM |  |  | 223 |
|  | &nbsp;&nbsp;&nbsp;ATMOS ENERGY CORP COM |  |  | 709 |
|  | &nbsp;&nbsp;&nbsp;AUTONATION INC COM |  |  | 142 |
|  | &nbsp;&nbsp;&nbsp;AVANGRID |  |  |  |
|  | &nbsp;&nbsp;&nbsp;AVANTOR INC COM |  |  | 470 |
|  | &nbsp;&nbsp;&nbsp;AVERY DENNISON CORP COM |  |  | 307 |
|  | &nbsp;&nbsp;&nbsp;AVIS BUDGET GROUP INC COM STK |  |  | 27 |
|  | &nbsp;&nbsp;&nbsp;AVNET INC COM |  |  | 149 |
|  | &nbsp;&nbsp;&nbsp;AXALTA COATING SYSTEMS LTD COM |  |  | 245 |
|  | &nbsp;&nbsp;&nbsp;AXIS CAPITAL HOLDINGS LTD COM |  |  | 224 |
|  | &nbsp;&nbsp;&nbsp;AZEK CO INC CL A |  |  | 67 |
|  | &nbsp;&nbsp;&nbsp;AZENTA INC COM |  |  | 79 |
|  | &nbsp;&nbsp;&nbsp;BAKER HUGHES CO |  |  | 1347 |
|  | &nbsp;&nbsp;&nbsp;BALL CORP COM |  |  | 536 |
|  | &nbsp;&nbsp;&nbsp;BANK NEW YORK MELLON CORP COM STK |  |  | 1868 |
|  | &nbsp;&nbsp;&nbsp;BANK OZK COM |  |  | 156 |
|  | &nbsp;&nbsp;&nbsp;BATH & BODY WORKS INC COM |  |  | 280 |
|  | &nbsp;&nbsp;&nbsp;BAXTER INTL INC COM |  |  | 489 |
|  | &nbsp;&nbsp;&nbsp;BELLRING BRANDS INC COM |  |  | 319 |
|  | &nbsp;&nbsp;&nbsp;BERKLEY W R CORP COM |  |  | 566 |
|  | &nbsp;&nbsp;&nbsp;BERRY GLOBAL GROUP INC |  |  | 244 |
|  | &nbsp;&nbsp;&nbsp;BEST BUY INC COM STK |  |  | 608 |
|  | &nbsp;&nbsp;&nbsp;BILL HOLDINGS INC COM |  |  | 211 |
|  | &nbsp;&nbsp;&nbsp;BIO RAD LABORATORIES INC CL A |  |  | 204 |
|  | &nbsp;&nbsp;&nbsp;BIOGEN INC COMMON STOCK |  |  | 733 |
|  | &nbsp;&nbsp;&nbsp;BIOMARIN PHARMACEUTICAL INC COM |  |  | 408 |
|  | &nbsp;&nbsp;&nbsp;BIO-TECHNE CORP COM |  |  | 368 |
|  | &nbsp;&nbsp;&nbsp;BIRKENSTOCK HOLDING PLC COM NPV |  |  | 73 |
|  | &nbsp;&nbsp;&nbsp;BJS WHSL CLUB HLDGS INC COM |  |  | 388 |
|  | &nbsp;&nbsp;&nbsp;BLOCK H & R INC COM |  |  | 195 |
|  | &nbsp;&nbsp;&nbsp;BLOCK INC |  |  | 898 |
|  | &nbsp;&nbsp;&nbsp;BOK FINL CORP COM NEW |  |  | 79 |
|  | &nbsp;&nbsp;&nbsp;BORG WARNER INC COM |  |  | 227 |
|  | &nbsp;&nbsp;&nbsp;BOSTON BEER INC CL A |  |  | 68 |
|  | &nbsp;&nbsp;&nbsp;BOYD GAMING CORP COM |  |  | 151 |
|  | &nbsp;&nbsp;&nbsp;BRIGHT HORIZONS FA COM |  |  | 179 |
|  | &nbsp;&nbsp;&nbsp;BRIGHTHOUSE FINL INC COM |  |  | 95 |
|  | &nbsp;&nbsp;&nbsp;BROADRIDGE FINL SOLUTIONS INC COM STK |  |  | 76 |
|  | &nbsp;&nbsp;&nbsp;BROOKFIELD RENEWABLE CORP NEW CL A |  |  | 123 |
|  | &nbsp;&nbsp;&nbsp;BROWN & BROWN INC COM |  |  | 449 |
|  | &nbsp;&nbsp;&nbsp;BROWN FORMAN CORP CL A |  |  | 59 |
|  | &nbsp;&nbsp;&nbsp;BROWN-FORMAN INC CL B NON-VTG COM |  |  | 217 |
|  | &nbsp;&nbsp;&nbsp;BRUKER CORP |  |  | 77 |
|  | &nbsp;&nbsp;&nbsp;BRUNSWICK CORP COM |  |  | 139 |
|  | &nbsp;&nbsp;&nbsp;BUILDERS FIRSTSOURCE INC COM STK |  |  | 490 |
|  | &nbsp;&nbsp;&nbsp;BUNGE GLOBAL SA F COMMON STOCK |  |  | 355 |
|  | &nbsp;&nbsp;&nbsp;BWX TECHNOLOGIES INC COM |  |  | 266 |
|  | &nbsp;&nbsp;&nbsp;C H ROBINSON WORLDWIDE INC COM NEW |  |  | 395 |
|  | &nbsp;&nbsp;&nbsp;CACI INTL INC CL A |  |  | 293 |
|  | &nbsp;&nbsp;&nbsp;CAESARS ENTMT INC NEW COM |  |  | 232 |
|  | &nbsp;&nbsp;&nbsp;CAPRI HOLDINGS LTD COM NPV |  |  | 79 |
|  | &nbsp;&nbsp;&nbsp;CARDINAL HLTH INC |  |  | 384 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;CARLISLE COMPANIES INC COM |  |  | 474 |
|  | &nbsp;&nbsp;&nbsp;CARLYLE GROUP INC COM |  |  | 364 |
|  | &nbsp;&nbsp;&nbsp;CARMAX INC COM |  |  | 387 |
|  | &nbsp;&nbsp;&nbsp;CARNIVAL CORP COM PAIRED |  |  | 841 |
|  | &nbsp;&nbsp;&nbsp;CARTER INC F |  |  | 63 |
|  | &nbsp;&nbsp;&nbsp;CARVANA CO CL A |  |  | 471 |
|  | &nbsp;&nbsp;&nbsp;CASEYS GEN STORES INC COM |  |  | 399 |
|  | &nbsp;&nbsp;&nbsp;CBOE GLOBAL MARKETS INC |  |  | 678 |
|  | &nbsp;&nbsp;&nbsp;CBRE GROUP INC CL A CL A |  |  | 1321 |
|  | &nbsp;&nbsp;&nbsp;CCC INTELLIGENT SOLUTIONS HLDGS INC COM |  |  | 174 |
|  | &nbsp;&nbsp;&nbsp;CDW CORP COM |  |  | 382 |
|  | &nbsp;&nbsp;&nbsp;CELANESE CORP DEL COM STK |  |  | 185 |
|  | &nbsp;&nbsp;&nbsp;CENTENE CORP DEL COM |  |  | 1006 |
|  | &nbsp;&nbsp;&nbsp;CENTERPOINT ENERGY INC COM |  |  | 674 |
|  | &nbsp;&nbsp;&nbsp;CERTARA INC COM |  |  | 42 |
|  | &nbsp;&nbsp;&nbsp;CF INDS HLDGS INC COM |  |  | 487 |
|  | &nbsp;&nbsp;&nbsp;CHARLES RIV LABORATORIES INTL INC COM |  |  | 310 |
|  | &nbsp;&nbsp;&nbsp;CHARTER COMMUNICATIONS INC NEW CL A CL A |  |  | 1058 |
|  | &nbsp;&nbsp;&nbsp;CHEMED CORP NEW COM |  |  | 233 |
|  | &nbsp;&nbsp;&nbsp;CHEMOURS CO COM |  |  | 77 |
|  | &nbsp;&nbsp;&nbsp;CHENIERE ENERGY INC COM NEW |  |  | 772 |
|  | &nbsp;&nbsp;&nbsp;CHOICE HOTELS INTL INC COM |  |  | 20 |
|  | &nbsp;&nbsp;&nbsp;CHORD ENERGY CORPORATION COM |  |  | 237 |
|  | &nbsp;&nbsp;&nbsp;CHURCH & DWIGHT INC COM |  |  | 840 |
|  | &nbsp;&nbsp;&nbsp;CIENA CORP COM NEW |  |  | 401 |
|  | &nbsp;&nbsp;&nbsp;CIN FNCL CORP COM |  |  | 724 |
|  | &nbsp;&nbsp;&nbsp;CIRRUS LOGIC INC COM |  |  | 176 |
|  | &nbsp;&nbsp;&nbsp;CITIZENS FINL GROUP INC COM |  |  | 643 |
|  | &nbsp;&nbsp;&nbsp;CIVITAS RES INC COM |  |  | 107 |
|  | &nbsp;&nbsp;&nbsp;CLARIVATE PLC |  |  | 68 |
|  | &nbsp;&nbsp;&nbsp;CLEAN HBRS INC COM |  |  | 385 |
|  | &nbsp;&nbsp;&nbsp;CLEARWAY ENERGY INC CL A CL A |  |  | 28 |
|  | &nbsp;&nbsp;&nbsp;CLEARWAY ENERGY INC CL C CL C |  |  | 70 |
|  | &nbsp;&nbsp;&nbsp;CLEVELAND CLIFFS |  |  | 100 |
|  | &nbsp;&nbsp;&nbsp;CMS ENERGY CORP COM |  |  | 654 |
|  | &nbsp;&nbsp;&nbsp;CNA FNCL CORP COM |  |  | 34 |
|  | &nbsp;&nbsp;&nbsp;CNH INDUSTRIAL NV COM STK |  |  | 325 |
|  | &nbsp;&nbsp;&nbsp;COCA-COLA CONSOLIDATED INC COM |  |  | 251 |
|  | &nbsp;&nbsp;&nbsp;COGNEX CORP COM |  |  | 192 |
|  | &nbsp;&nbsp;&nbsp;COGNIZANT TECH SOLUTIONS CORP CL A |  |  | 1259 |
|  | &nbsp;&nbsp;&nbsp;COHERENT CORP COM |  |  | 389 |
|  | &nbsp;&nbsp;&nbsp;COINBASE GLOBAL INC COM CL A |  |  | 265 |
|  | &nbsp;&nbsp;&nbsp;COLUMBIA BKG SYS INC COM |  |  | 185 |
|  | &nbsp;&nbsp;&nbsp;COLUMBIA SPORTSWEAR CO COM |  |  | 90 |
|  | &nbsp;&nbsp;&nbsp;COM ALCOA CORPORATION COM |  |  | 307 |
|  | &nbsp;&nbsp;&nbsp;COMERICA INC COM |  |  | 270 |
|  | &nbsp;&nbsp;&nbsp;COMM BANCSHARES INC COM |  |  | 252 |
|  | &nbsp;&nbsp;&nbsp;CONAGRA BRANDS INC COM USD5 |  |  | 435 |
|  | &nbsp;&nbsp;&nbsp;CONCENTRIX CORP |  |  | 67 |
|  | &nbsp;&nbsp;&nbsp;CONS EDISON INC COM |  |  | 1017 |
|  | &nbsp;&nbsp;&nbsp;CORE & MAIN INC COM CL A COM CL A |  |  | 110 |
|  | &nbsp;&nbsp;&nbsp;COREBRIDGE FINL INC COM |  |  | 291 |
|  | &nbsp;&nbsp;&nbsp;CORNING INC COM |  |  | 1198 |
|  | &nbsp;&nbsp;&nbsp;CORTEVA INC COM |  |  | 1311 |
|  | &nbsp;&nbsp;&nbsp;COSTAR GROUP INC COM |  |  | 956 |
|  | &nbsp;&nbsp;&nbsp;COTERRA ENERGY INC COM |  |  | 612 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;COTY INC COM CL A COM CL A |  |  | 87 |
|  | &nbsp;&nbsp;&nbsp;CRANE CO NEW COM |  |  | 244 |
|  | &nbsp;&nbsp;&nbsp;CRANE NXT CO COM |  |  | 94 |
|  | &nbsp;&nbsp;&nbsp;CREDIT ACCEP CORP MICH COM |  |  | 21 |
|  | &nbsp;&nbsp;&nbsp;CROCS INC COM |  |  | 169 |
|  | &nbsp;&nbsp;&nbsp;CROWN HLDGS INC COM |  |  | 318 |
|  | &nbsp;&nbsp;&nbsp;CULLEN / FROST BANKERS INC COM |  |  | 260 |
|  | &nbsp;&nbsp;&nbsp;CUMMINS INC |  |  | 1567 |
|  | &nbsp;&nbsp;&nbsp;CURTISS WRIGHT CORP COM |  |  | 445 |
|  | &nbsp;&nbsp;&nbsp;D R HORTON INC COM |  |  | 1342 |
|  | &nbsp;&nbsp;&nbsp;DARDEN RESTAURANTS INC COM |  |  | 338 |
|  | &nbsp;&nbsp;&nbsp;DARLING INGREDIENTS INC COMSTK |  |  | 176 |
|  | &nbsp;&nbsp;&nbsp;DAYFORCE INC |  |  | 322 |
|  | &nbsp;&nbsp;&nbsp;DELTA AIR LINES INC DEL COM NEW COM NEW |  |  | 1282 |
|  | &nbsp;&nbsp;&nbsp;DENTSPLY SIRONA INC COM |  |  | 126 |
|  | &nbsp;&nbsp;&nbsp;DEVON ENERGY CORP NEW COM |  |  | 671 |
|  | &nbsp;&nbsp;&nbsp;DIAMONDBACK ENERGY INC COM |  |  | 1017 |
|  | &nbsp;&nbsp;&nbsp;DICKS SPORTING GOODS INC OC-COM OC-COM |  |  | 383 |
|  | &nbsp;&nbsp;&nbsp;DILLARDS INC CL A COM |  |  | 44 |
|  | &nbsp;&nbsp;&nbsp;DISCOVER FINL SVCS COM STK |  |  | 1425 |
|  | &nbsp;&nbsp;&nbsp;DOLBY LABORATORIES INC CL A COM STK |  |  | 150 |
|  | &nbsp;&nbsp;&nbsp;DOLLAR GEN CORP NEW COM |  |  | 548 |
|  | &nbsp;&nbsp;&nbsp;DOLLAR TREE INC COM STK |  |  | 499 |
|  | &nbsp;&nbsp;&nbsp;DOMINOS PIZZA INC COM |  |  | 313 |
|  | &nbsp;&nbsp;&nbsp;DONALDSON INC COM |  |  | 266 |
|  | &nbsp;&nbsp;&nbsp;DOUBLEVERIFY HLDGS INC COM |  |  | 40 |
|  | &nbsp;&nbsp;&nbsp;DOVER CORP COM |  |  | 846 |
|  | &nbsp;&nbsp;&nbsp;DOW INC |  |  | 929 |
|  | &nbsp;&nbsp;&nbsp;DOXIMITY INC COM |  |  | 199 |
|  | &nbsp;&nbsp;&nbsp;DROPBOX INC CL A CL A |  |  | 163 |
|  | &nbsp;&nbsp;&nbsp;DT MIDSTREAM INC COM |  |  | 317 |
|  | &nbsp;&nbsp;&nbsp;DTE ENERGY CO COM |  |  | 821 |
|  | &nbsp;&nbsp;&nbsp;DUN & BRADSTREET HLDGS INC COM |  |  | 124 |
|  | &nbsp;&nbsp;&nbsp;DUPONT DE NEMOURS INC COMMON STOCK |  |  | 1049 |
|  | &nbsp;&nbsp;&nbsp;DUTCH BROS INC CL A CL A |  |  | 114 |
|  | &nbsp;&nbsp;&nbsp;DXC TECHNOLOGY CO COM |  |  | 118 |
|  | &nbsp;&nbsp;&nbsp;EAGLE MATLS INC COM |  |  | 66 |
|  | &nbsp;&nbsp;&nbsp;EAST WEST BANCORP INC COM |  |  | 434 |
|  | &nbsp;&nbsp;&nbsp;EASTMAN CHEM CO COM |  |  | 351 |
|  | &nbsp;&nbsp;&nbsp;EBAY INC COM |  |  | 975 |
|  | &nbsp;&nbsp;&nbsp;EDISON INTL COM |  |  | 1000 |
|  | &nbsp;&nbsp;&nbsp;ELANCO ANIMAL HEALTH INC COM |  |  | 196 |
|  | &nbsp;&nbsp;&nbsp;ELECTR ARTS COM |  |  | 1272 |
|  | &nbsp;&nbsp;&nbsp;ELEMENT SOLUTION INC COM |  |  | 187 |
|  | &nbsp;&nbsp;&nbsp;EMCOR GROUP INC COM |  |  | 411 |
|  | &nbsp;&nbsp;&nbsp;ENCOMPASS HEALTH CORP COM |  |  | 301 |
|  | &nbsp;&nbsp;&nbsp;ENOVIS CORPORATION COM |  |  | 80 |
|  | &nbsp;&nbsp;&nbsp;ENTERGY CORP NEW COM |  |  | 1063 |
|  | &nbsp;&nbsp;&nbsp;ENVISTA HLDGS CORP COM |  |  | 109 |
|  | &nbsp;&nbsp;&nbsp;EPAM SYS INC COM STK |  |  | 394 |
|  | &nbsp;&nbsp;&nbsp;EQT CORP COM |  |  | 838 |
|  | &nbsp;&nbsp;&nbsp;EQUIFAX INC COM |  |  | 823 |
|  | &nbsp;&nbsp;&nbsp;ESAB CORPORATION COM |  |  | 223 |
|  | &nbsp;&nbsp;&nbsp;ESSENTIAL UTILS INC COM |  |  | 301 |
|  | &nbsp;&nbsp;&nbsp;ETSY INC COM |  |  | 68 |
|  | &nbsp;&nbsp;&nbsp;EURONET WORLDWIDE INC COM |  |  | 143 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;EVERCORE INC |  |  | 327 |
|  | &nbsp;&nbsp;&nbsp;EVEREST GROUP LTD |  |  | 430 |
|  | &nbsp;&nbsp;&nbsp;EVERGY INC COM NPV |  |  | 452 |
|  | &nbsp;&nbsp;&nbsp;EVERSOURCE ENERGY COM |  |  | 676 |
|  | &nbsp;&nbsp;&nbsp;EVERUS CONSTR GROUP INC COM |  |  | 110 |
|  | &nbsp;&nbsp;&nbsp;EXACT SCIENCES CORP COM |  |  | 204 |
|  | &nbsp;&nbsp;&nbsp;EXELIXIS INC COM STK |  |  | 51 |
|  | &nbsp;&nbsp;&nbsp;EXELON CORP COM |  |  | 1239 |
|  | &nbsp;&nbsp;&nbsp;EXPAND ENERGY CORP |  |  | 755 |
|  | &nbsp;&nbsp;&nbsp;EXPEDITORS INTL WASH INC COM |  |  | 431 |
|  | &nbsp;&nbsp;&nbsp;F N B CORP PA COM |  |  | 172 |
|  | &nbsp;&nbsp;&nbsp;F5 INC COM STK NPV |  |  | 483 |
|  | &nbsp;&nbsp;&nbsp;FACTSET RESH SYS INC COM STK |  |  | 389 |
|  | &nbsp;&nbsp;&nbsp;FAIR ISAAC CORPORATION COM |  |  | 239 |
|  | &nbsp;&nbsp;&nbsp;FASTENAL CO COM |  |  | 213 |
|  | &nbsp;&nbsp;&nbsp;FERGUSON ENTERPRISES INC |  |  | 1078 |
|  | &nbsp;&nbsp;&nbsp;FIDELITY NATL FINL INC |  |  | 479 |
|  | &nbsp;&nbsp;&nbsp;FIDELITY NATL INFORMATION SVCS INC COM STK |  |  | 1451 |
|  | &nbsp;&nbsp;&nbsp;FIRST AMERN FINL CORP COM STK |  |  | 205 |
|  | &nbsp;&nbsp;&nbsp;FIRST CTZNS BANCSHARES INC CL A CL A |  |  | 833 |
|  | &nbsp;&nbsp;&nbsp;FIRST HAWAIIAN INC COM |  |  | 108 |
|  | &nbsp;&nbsp;&nbsp;FIRST HORIZON CORPORATION COM |  |  | 353 |
|  | &nbsp;&nbsp;&nbsp;FIRST SOLAR INC COM |  |  | 618 |
|  | &nbsp;&nbsp;&nbsp;FIRSTENERGY CORP COM |  |  | 754 |
|  | &nbsp;&nbsp;&nbsp;FIVE BELOW INC COM |  |  | 38 |
|  | &nbsp;&nbsp;&nbsp;FLOOR & DECOR HLDGS INC CL A |  |  | 219 |
|  | &nbsp;&nbsp;&nbsp;FLOWERS FOODS INC COM |  |  | 126 |
|  | &nbsp;&nbsp;&nbsp;FLOWSERVE CORP COM |  |  | 248 |
|  | &nbsp;&nbsp;&nbsp;FMC CORP COM (NEW) |  |  | 199 |
|  | &nbsp;&nbsp;&nbsp;FORTIVE CORP COM MON STOCK |  |  | 855 |
|  | &nbsp;&nbsp;&nbsp;FORTREA HLDGS INC COM |  |  | 49 |
|  | &nbsp;&nbsp;&nbsp;FORTUNE BRANDS INNOVATIONS INC |  |  | 277 |
|  | &nbsp;&nbsp;&nbsp;FOX CORP CL A CL A |  |  | 352 |
|  | &nbsp;&nbsp;&nbsp;FOX CORP CL B CL B |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;FRESHPET INC COM |  |  | 154 |
|  | &nbsp;&nbsp;&nbsp;FRKLN RES INC COM |  |  | 191 |
|  | &nbsp;&nbsp;&nbsp;FRONTIER COMMUNICATIONS PARENT INC COM NPV |  |  | 280 |
|  | &nbsp;&nbsp;&nbsp;FTI CONSULTING INC COM |  |  | 221 |
|  | &nbsp;&nbsp;&nbsp;GALLAGHER ARTHUR J & CO COM |  |  | 2137 |
|  | &nbsp;&nbsp;&nbsp;GAMESTOP CORP NEW CL A |  |  | 405 |
|  | &nbsp;&nbsp;&nbsp;GAP INC COM |  |  | 158 |
|  | &nbsp;&nbsp;&nbsp;GARMIN LTD COMMON STOCK |  |  | 1051 |
|  | &nbsp;&nbsp;&nbsp;GATES INDL CORP PL COM |  |  | 160 |
|  | &nbsp;&nbsp;&nbsp;GE HEALTHCARE TECHNOLOGIES INC COM |  |  | 1060 |
|  | &nbsp;&nbsp;&nbsp;GEN DIGITAL INC COM |  |  | 490 |
|  | &nbsp;&nbsp;&nbsp;GENERAC HLDGS INC COM STK |  |  | 153 |
|  | &nbsp;&nbsp;&nbsp;GENERAL MILLS INC COM |  |  | 1172 |
|  | &nbsp;&nbsp;&nbsp;GENPACT LIMITED COM STK |  |  | 245 |
|  | &nbsp;&nbsp;&nbsp;GENTEX CORP COM |  |  | 218 |
|  | &nbsp;&nbsp;&nbsp;GENUINE PARTS CO COM |  |  | 534 |
|  | &nbsp;&nbsp;&nbsp;GLOBAL PMTS INC COM |  |  | 938 |
|  | &nbsp;&nbsp;&nbsp;GLOBALFOUNDRIES INC |  |  | 139 |
|  | &nbsp;&nbsp;&nbsp;GLOBANT SA USD1.20 |  |  | 73 |
|  | &nbsp;&nbsp;&nbsp;GLOBE LIFE INC COM |  |  | 326 |
|  | &nbsp;&nbsp;&nbsp;GLOBUS MED INC CL A NEW COM STK |  |  | 304 |
|  | &nbsp;&nbsp;&nbsp;GRACO INC COM |  |  | 464 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;GRAIL INC COM |  |  | 15 |
|  | &nbsp;&nbsp;&nbsp;GRAINGER W W INC COM |  |  | 198 |
|  | &nbsp;&nbsp;&nbsp;GRAND CANYON ED INC COM STK |  |  | 106 |
|  | &nbsp;&nbsp;&nbsp;GRAPHIC PACKAGING HLDG CO COM STK |  |  | 265 |
|  | &nbsp;&nbsp;&nbsp;GROCERY OUTLET HLDG CORP COM |  |  | 49 |
|  | &nbsp;&nbsp;&nbsp;GUIDEWIRE SOFTWARE INC COM |  |  | 247 |
|  | &nbsp;&nbsp;&nbsp;GXO LOGISTICS INC COM |  |  | 168 |
|  | &nbsp;&nbsp;&nbsp;HALLIBURTON CO COM |  |  | 789 |
|  | &nbsp;&nbsp;&nbsp;HANOVER INS GROUP INC COM |  |  | 181 |
|  | &nbsp;&nbsp;&nbsp;HARLEY DAVIDSON COM |  |  | 117 |
|  | &nbsp;&nbsp;&nbsp;HASBRO INC COM |  |  | 32 |
|  | &nbsp;&nbsp;&nbsp;HASHICORP INC |  |  | 35 |
|  | &nbsp;&nbsp;&nbsp;HAYWARD HLDGS INC COM |  |  | 71 |
|  | &nbsp;&nbsp;&nbsp;HENRY SCHEIN INC COMMON STOCK |  |  | 287 |
|  | &nbsp;&nbsp;&nbsp;HERSHEY COMPANY COM STK |  |  | 699 |
|  | &nbsp;&nbsp;&nbsp;HESS CORP COM STK |  |  | 432 |
|  | &nbsp;&nbsp;&nbsp;HEWLETT PACKARD ENTERPRISE CO COM |  |  | 911 |
|  | &nbsp;&nbsp;&nbsp;HEXCEL CORP NEW COM |  |  | 168 |
|  | &nbsp;&nbsp;&nbsp;HF SINCLAIR CORPORATION COM |  |  | 178 |
|  | &nbsp;&nbsp;&nbsp;HILTON WORLDWIDE HLDGS INC COM NEW |  |  | 950 |
|  | &nbsp;&nbsp;&nbsp;HOLOGIC INC COM |  |  | 542 |
|  | &nbsp;&nbsp;&nbsp;HORMEL FOODS CORP COM |  |  | 299 |
|  | &nbsp;&nbsp;&nbsp;HOULIHAN LOKEY INC CL A CL A |  |  | 273 |
|  | &nbsp;&nbsp;&nbsp;HOWARD HUGHES HLDGS INC COM |  |  | 78 |
|  | &nbsp;&nbsp;&nbsp;HOWMET AEROSPACE INC COM |  |  | 1369 |
|  | &nbsp;&nbsp;&nbsp;HP INC COM |  |  | 784 |
|  | &nbsp;&nbsp;&nbsp;HUBBELL INC COM |  |  | 738 |
|  | &nbsp;&nbsp;&nbsp;HUMANA INC COM |  |  | 1007 |
|  | &nbsp;&nbsp;&nbsp;HUNT J B TRANS SVCS INC COM |  |  | 455 |
|  | &nbsp;&nbsp;&nbsp;HUNTINGTON BANCSHARES INC COM |  |  | 772 |
|  | &nbsp;&nbsp;&nbsp;HUNTINGTON INGALLS INDS INC COM |  |  | 242 |
|  | &nbsp;&nbsp;&nbsp;HUNTSMAN CORP COM STK |  |  | 96 |
|  | &nbsp;&nbsp;&nbsp;HYATT HOTELS CORP COM CL A COM CL A |  |  | 181 |
|  | &nbsp;&nbsp;&nbsp;IAC INC COM NEW |  |  | 105 |
|  | &nbsp;&nbsp;&nbsp;IDACORP INC COM |  |  | 191 |
|  | &nbsp;&nbsp;&nbsp;IDEX CORP COM |  |  | 521 |
|  | &nbsp;&nbsp;&nbsp;ILLUMINA INC COM |  |  | 700 |
|  | &nbsp;&nbsp;&nbsp;INCYTE CORP COM |  |  | 340 |
|  | &nbsp;&nbsp;&nbsp;INFORMATICA INC CL A CL A |  |  | 69 |
|  | &nbsp;&nbsp;&nbsp;INGERSOLL RAND INC COM |  |  | 1201 |
|  | &nbsp;&nbsp;&nbsp;INGRAM MICRO HLDG CORP COM |  |  | 8 |
|  | &nbsp;&nbsp;&nbsp;INGREDION INC COM |  |  | 297 |
|  | &nbsp;&nbsp;&nbsp;INTERACTIVE BROKERS GROUP INC CL COM |  |  | 614 |
|  | &nbsp;&nbsp;&nbsp;INTERPUBLIC GROUP COMPANIES INC COM |  |  | 343 |
|  | &nbsp;&nbsp;&nbsp;INTL FLAVORS & FRAGRANCES INC COM |  |  | 711 |
|  | &nbsp;&nbsp;&nbsp;INTL PAPER CO COM |  |  | 613 |
|  | &nbsp;&nbsp;&nbsp;INVESCO LTD COM STK USD0.20 |  |  | 210 |
|  | &nbsp;&nbsp;&nbsp;IONIS PHARMACEUTICALS INC COM |  |  | 12 |
|  | &nbsp;&nbsp;&nbsp;IPG PHOTONICS CORP COM |  |  | 65 |
|  | &nbsp;&nbsp;&nbsp;IQVIA HLDGS INC COM |  |  | 1033 |
|  | &nbsp;&nbsp;&nbsp;IRIDIUM COMMUNICATIONS INC COM STK |  |  | 97 |
|  | &nbsp;&nbsp;&nbsp;ITT INC COM |  |  | 387 |
|  | &nbsp;&nbsp;&nbsp;JABIL INC COM USD0.001 |  |  | 480 |
|  | &nbsp;&nbsp;&nbsp;JACK HENRY & ASSOC INC COM |  |  | 418 |
|  | &nbsp;&nbsp;&nbsp;JACOBS SOLUTIONS INC COM |  |  | 542 |
|  | &nbsp;&nbsp;&nbsp;JANUS HENDERSON GROUP PLC |  |  | 179 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;JAZZ PHARMACEUTICALS PLC COM |  |  | 244 |
|  | &nbsp;&nbsp;&nbsp;JEFFERIES FINL GROUP INC COM |  |  | 323 |
|  | &nbsp;&nbsp;&nbsp;JONES LANG LASALLE INC COM STK |  |  | 272 |
|  | &nbsp;&nbsp;&nbsp;JUNIPER NETWORKS INC COM |  |  | 401 |
|  | &nbsp;&nbsp;&nbsp;KBR INC COM |  |  | 232 |
|  | &nbsp;&nbsp;&nbsp;KELLANOVA COM |  |  | 698 |
|  | &nbsp;&nbsp;&nbsp;KEMPER CORP DEL COM |  |  | 132 |
|  | &nbsp;&nbsp;&nbsp;KENVUE INC COM |  |  | 1345 |
|  | &nbsp;&nbsp;&nbsp;KEYCORP NEW COM |  |  | 522 |
|  | &nbsp;&nbsp;&nbsp;KEYSIGHT TECHNOLOGIES INC COM |  |  | 921 |
|  | &nbsp;&nbsp;&nbsp;KINDER MORGAN INC DEL COM |  |  | 1747 |
|  | &nbsp;&nbsp;&nbsp;KIRBY CORP COM |  |  | 202 |
|  | &nbsp;&nbsp;&nbsp;KNIGHT-SWIFT TRANSN HLDGS INC CL A |  |  | 272 |
|  | &nbsp;&nbsp;&nbsp;KOHLS CORP COM |  |  | 51 |
|  | &nbsp;&nbsp;&nbsp;KROGER CO COM |  |  | 1335 |
|  | &nbsp;&nbsp;&nbsp;KYNDRYL HLDGS INC COM |  |  | 259 |
|  | &nbsp;&nbsp;&nbsp;L3HARRIS TECHNOLOGIES INC COM |  |  | 1310 |
|  | &nbsp;&nbsp;&nbsp;LABCORP HLDGS INC COM |  |  | 634 |
|  | &nbsp;&nbsp;&nbsp;LAMB WESTON HLDGS INC COM USD5 |  |  | 212 |
|  | &nbsp;&nbsp;&nbsp;LANDSTAR SYS INC COM |  |  | 199 |
|  | &nbsp;&nbsp;&nbsp;LATTICE SEMICONDUCTOR CORP COM |  |  | 34 |
|  | &nbsp;&nbsp;&nbsp;LEAR CORP COM NEW COM NEW |  |  | 168 |
|  | &nbsp;&nbsp;&nbsp;LEGGETT & PLATT INC COM |  |  | 42 |
|  | &nbsp;&nbsp;&nbsp;LEIDOS HLDGS INC COM |  |  | 630 |
|  | &nbsp;&nbsp;&nbsp;LENNAR CORP CL A CL A |  |  | 1056 |
|  | &nbsp;&nbsp;&nbsp;LENNAR CORP CL B CL B |  |  | 47 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY BROADBAND CORP COM SER A COM SERA |  |  | 29 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY BROADBAND CORP COM SER C COM SERC |  |  | 206 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY GLOBAL LTD. COM CLASS C |  |  | 65 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY GLOBAL LTD. COMMON STOCK |  |  | 70 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER A |  |  | 40 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER C |  |  | 413 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER A |  |  | 43 |
|  | &nbsp;&nbsp;&nbsp;LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER C |  |  | 104 |
|  | &nbsp;&nbsp;&nbsp;LINCOLN ELEC HLDGS INC COM |  |  | 245 |
|  | &nbsp;&nbsp;&nbsp;LINCOLN NATL CORP COM |  |  | 177 |
|  | &nbsp;&nbsp;&nbsp;LITHIA MTRS INC COM CL A |  |  | 308 |
|  | &nbsp;&nbsp;&nbsp;LITTELFUSE INC COM |  |  | 189 |
|  | &nbsp;&nbsp;&nbsp;LKQ CORP COM LKQ CORP |  |  | 313 |
|  | &nbsp;&nbsp;&nbsp;LOAR HOLDINGS INC COM |  |  | 7 |
|  | &nbsp;&nbsp;&nbsp;LOEWS CORP COM |  |  | 498 |
|  | &nbsp;&nbsp;&nbsp;LOUISIANA-PACIFIC CORP COM |  |  | 64 |
|  | &nbsp;&nbsp;&nbsp;LUCID GROUP INC COM |  |  | 98 |
|  | &nbsp;&nbsp;&nbsp;LUMENTUM HLDGS INC COM |  |  | 188 |
|  | &nbsp;&nbsp;&nbsp;LYFT INC CL A CL A |  |  | 48 |
|  | &nbsp;&nbsp;&nbsp;LYONDELLBASELL IND N V COM |  |  | 636 |
|  | &nbsp;&nbsp;&nbsp;M & T BK CORP COM |  |  | 1028 |
|  | &nbsp;&nbsp;&nbsp;MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC COM STK |  |  | 238 |
|  | &nbsp;&nbsp;&nbsp;MACYS INC COM STK |  |  | 152 |
|  | &nbsp;&nbsp;&nbsp;MADISON SQUARE GARDEN SPORTS CORP |  |  | 127 |
|  | &nbsp;&nbsp;&nbsp;MANPOWERGROUP INC |  |  | 89 |
|  | &nbsp;&nbsp;&nbsp;MAPLEBEAR INC COM |  |  | 227 |
|  | &nbsp;&nbsp;&nbsp;MARKEL GROUP INC |  |  | 549 |
|  | &nbsp;&nbsp;&nbsp;MARKETAXESS HLDGS INC COM STK |  |  | 275 |
|  | &nbsp;&nbsp;&nbsp;MARRIOTT VACATIONS WORLDWIDE CORP COM |  |  | 103 |
|  | &nbsp;&nbsp;&nbsp;MARTIN MARIETTA MATLS INC COM |  |  | 983 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;MASCO CORP COM |  |  | 515 |
|  | &nbsp;&nbsp;&nbsp;MASIMO CORP COM STK |  |  | 113 |
|  | &nbsp;&nbsp;&nbsp;MASTEC INC COM |  |  | 281 |
|  | &nbsp;&nbsp;&nbsp;MATADOR RES CO COM |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;MATCH GROUP INC NEW COM |  |  | 277 |
|  | &nbsp;&nbsp;&nbsp;MATTEL INC COM STOCK |  |  | 197 |
|  | &nbsp;&nbsp;&nbsp;MC CORMICK & CO INC COM NON-VTG |  |  | 632 |
|  | &nbsp;&nbsp;&nbsp;MDU RES GROUP INC COM |  |  | 120 |
|  | &nbsp;&nbsp;&nbsp;METTLER-TOLEDO INTL INC COM |  |  | 849 |
|  | &nbsp;&nbsp;&nbsp;MGIC INVT CORP WIS COM |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;MGM RESORTS INTERNATIONAL COM |  |  | 261 |
|  | &nbsp;&nbsp;&nbsp;MICROCHIP TECHNOLOGY INC COM |  |  | 1000 |
|  | &nbsp;&nbsp;&nbsp;MICROSTRATEGY INC CL A NEW CL A NEW |  |  | 1470 |
|  | &nbsp;&nbsp;&nbsp;MIDDLEBY CORP COM |  |  | 237 |
|  | &nbsp;&nbsp;&nbsp;MKS INSTRS INC COM |  |  | 216 |
|  | &nbsp;&nbsp;&nbsp;MLP VIPER ENERGY INC |  |  | 117 |
|  | &nbsp;&nbsp;&nbsp;MOHAWK INDS INC COM |  |  | 205 |
|  | &nbsp;&nbsp;&nbsp;MOLINA HEALTHCARE INC COM |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;MOLSON COORS BEVERAGE COMPANY COM CLASS B |  |  | 322 |
|  | &nbsp;&nbsp;&nbsp;MOSAIC CO/THE |  |  | 259 |
|  | &nbsp;&nbsp;&nbsp;MP MATERIALS CORP COM |  |  | 67 |
|  | &nbsp;&nbsp;&nbsp;MSA SAFETY INC COM |  |  | 202 |
|  | &nbsp;&nbsp;&nbsp;MSC INDL DIRECT INC CL A COM |  |  | 112 |
|  | &nbsp;&nbsp;&nbsp;MSCI INC COM |  |  | 632 |
|  | &nbsp;&nbsp;&nbsp;NASDAQ INC |  |  | 1048 |
|  | &nbsp;&nbsp;&nbsp;NATL FUEL GAS CO COM |  |  | 182 |
|  | &nbsp;&nbsp;&nbsp;NCINO INC NEW COM |  |  | 35 |
|  | &nbsp;&nbsp;&nbsp;NETAPP INC COM STK |  |  | 434 |
|  | &nbsp;&nbsp;&nbsp;NEW FORTRESS INC CL A |  |  | 19 |
|  | &nbsp;&nbsp;&nbsp;NEW YORK TIMES CO CL A |  |  | 275 |
|  | &nbsp;&nbsp;&nbsp;NEWELL BRANDS INC COM |  |  | 136 |
|  | &nbsp;&nbsp;&nbsp;NEWMARKET CORP COM |  |  | 117 |
|  | &nbsp;&nbsp;&nbsp;NEWS CORP COM CL A |  |  | 345 |
|  | &nbsp;&nbsp;&nbsp;NEWS CORP COM CL B |  |  | 113 |
|  | &nbsp;&nbsp;&nbsp;NEXSTAR MEDIA GROUP INC COMMON STOCK |  |  | 97 |
|  | &nbsp;&nbsp;&nbsp;NISOURCE INC COM |  |  | 563 |
|  | &nbsp;&nbsp;&nbsp;NORDSON CORP COM |  |  | 390 |
|  | &nbsp;&nbsp;&nbsp;NORDSTROM INC COM |  |  | 79 |
| &nbsp;&nbsp;\* | &nbsp;&nbsp;&nbsp;NORTHERN TR CORP COM |  |  | 661 |
|  | &nbsp;&nbsp;&nbsp;NOV INC COM |  |  | 186 |
|  | &nbsp;&nbsp;&nbsp;NRG ENERGY INC COM NEW |  |  | 361 |
|  | &nbsp;&nbsp;&nbsp;NUCOR CORP COM |  |  | 910 |
|  | &nbsp;&nbsp;&nbsp;NUTANIX INC CL A CL A |  |  | 361 |
|  | &nbsp;&nbsp;&nbsp;NVENT ELECTRIC PLC COM |  |  | 370 |
|  | &nbsp;&nbsp;&nbsp;NVR INC COM STK |  |  | 777 |
|  | &nbsp;&nbsp;&nbsp;OGE ENERGY CORP COM |  |  | 270 |
|  | &nbsp;&nbsp;&nbsp;OKTA INC CL A CL A |  |  | 232 |
|  | &nbsp;&nbsp;&nbsp;OLD REPUBLIC INTERNATIONAL CORP COM STK |  |  | 280 |
|  | &nbsp;&nbsp;&nbsp;OLIN CORP COM |  |  | 130 |
|  | &nbsp;&nbsp;&nbsp;OLLIES BARGAIN OUTLET HLDGS INC COM |  |  | 220 |
|  | &nbsp;&nbsp;&nbsp;OMNICOM GROUP INC COM |  |  | 548 |
|  | &nbsp;&nbsp;&nbsp;ON SEMICONDUCTOR CORP COM |  |  | 881 |
|  | &nbsp;&nbsp;&nbsp;ONEMAIN HLDGS INC COM |  |  | 194 |
|  | &nbsp;&nbsp;&nbsp;ONEOK INC COM STK |  |  | 1927 |
|  | &nbsp;&nbsp;&nbsp;ONTO INNOVATION INC |  |  | 200 |
|  | &nbsp;&nbsp;&nbsp;ORGANON & CO COM |  |  | 126 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;OSHKOSH CORPORATION |  |  | 204 |
|  | &nbsp;&nbsp;&nbsp;OTIS WORLDWIDE CORP COM |  |  | 1217 |
|  | &nbsp;&nbsp;&nbsp;OVINTIV INC COM |  |  | 351 |
|  | &nbsp;&nbsp;&nbsp;OWENS CORNING NEW COM STK |  |  | 483 |
|  | &nbsp;&nbsp;&nbsp;PACKAGING CORP AMER COM |  |  | 656 |
|  | &nbsp;&nbsp;&nbsp;PARAMOUNT GLOBAL COM CL A |  |  | 7 |
|  | &nbsp;&nbsp;&nbsp;PARAMOUNT GLOBAL COM CL B |  |  | 204 |
|  | &nbsp;&nbsp;&nbsp;PARSONS CORP DEL COM |  |  | 139 |
|  | &nbsp;&nbsp;&nbsp;PAYCHEX INC COM |  |  | 951 |
|  | &nbsp;&nbsp;&nbsp;PAYCOM SOFTWARE INC COM |  |  | 127 |
|  | &nbsp;&nbsp;&nbsp;PAYCOR HCM INC COM |  |  | 45 |
|  | &nbsp;&nbsp;&nbsp;PENN ENTERTAINMENT INC |  |  | 98 |
|  | &nbsp;&nbsp;&nbsp;PENSKE AUTOMOTIVE GROUP INC COM STK |  |  | 92 |
|  | &nbsp;&nbsp;&nbsp;PENTAIR PLC COM |  |  | 546 |
|  | &nbsp;&nbsp;&nbsp;PERFORMANCE FOOD GROUP CO COM |  |  | 364 |
|  | &nbsp;&nbsp;&nbsp;PERMIAN RES CORP CL A |  |  | 243 |
|  | &nbsp;&nbsp;&nbsp;PERRIGO COMPANY LIMITED COM |  |  | 114 |
|  | &nbsp;&nbsp;&nbsp;PG& E CORP COM |  |  | 1419 |
|  | &nbsp;&nbsp;&nbsp;PILGRIMS PRIDE CORP |  |  | 56 |
|  | &nbsp;&nbsp;&nbsp;PINNACLE FINL PARTNERS INC COM |  |  | 285 |
|  | &nbsp;&nbsp;&nbsp;PINNACLE W. CAP CORP COM |  |  | 317 |
|  | &nbsp;&nbsp;&nbsp;PLANET FITNESS INC CL A CL A |  |  | 126 |
|  | &nbsp;&nbsp;&nbsp;PLAYTIKA HLDG CORP COM |  |  | 16 |
|  | &nbsp;&nbsp;&nbsp;POLARIS INC |  |  | 97 |
|  | &nbsp;&nbsp;&nbsp;POPULAR INC COM NEW |  |  | 198 |
|  | &nbsp;&nbsp;&nbsp;POST HLDGS INC COM STK |  |  | 179 |
|  | &nbsp;&nbsp;&nbsp;PPG IND INC COM |  |  | 909 |
|  | &nbsp;&nbsp;&nbsp;PPL CORP COM |  |  | 788 |
|  | &nbsp;&nbsp;&nbsp;PREMIER INC CL A CL A |  |  | 67 |
|  | &nbsp;&nbsp;&nbsp;PRIMERICA INC COM |  |  | 301 |
|  | &nbsp;&nbsp;&nbsp;PRINCIPAL FINL GROUP INC COM STK |  |  | 578 |
|  | &nbsp;&nbsp;&nbsp;PROSPERITY BANCSHARES INC COM |  |  | 222 |
|  | &nbsp;&nbsp;&nbsp;PRUDENTIAL FINL INC COM |  |  | 1402 |
|  | &nbsp;&nbsp;&nbsp;PTC INC COM |  |  | 281 |
|  | &nbsp;&nbsp;&nbsp;PUB SERVICE ENTERPRISE GROUP INC COM |  |  | 1386 |
|  | &nbsp;&nbsp;&nbsp;PULTE GROUP INC |  |  | 731 |
|  | &nbsp;&nbsp;&nbsp;PURE STORAGE INC CL A CL A |  |  | 79 |
|  | &nbsp;&nbsp;&nbsp;PVH CORP COM |  |  | 193 |
|  | &nbsp;&nbsp;&nbsp;QIAGEN NV ORD |  |  | 327 |
|  | &nbsp;&nbsp;&nbsp;QORVO INC COM |  |  | 218 |
|  | &nbsp;&nbsp;&nbsp;QUANTA SVCS INC COM |  |  | 1048 |
|  | &nbsp;&nbsp;&nbsp;QUANTUMSCAPE CORP COM CL A |  |  | 61 |
|  | &nbsp;&nbsp;&nbsp;QUEST DIAGNOSTICS INC COM |  |  | 551 |
|  | &nbsp;&nbsp;&nbsp;QUIDELORTHO CORPORATION |  |  | 91 |
|  | &nbsp;&nbsp;&nbsp;RALPH LAUREN CORP CL A CL A |  |  | 300 |
|  | &nbsp;&nbsp;&nbsp;RANGE RES CORP COM |  |  | 281 |
|  | &nbsp;&nbsp;&nbsp;RAYMOND JAMES FNCL INC COM STK |  |  | 940 |
|  | &nbsp;&nbsp;&nbsp;RB GLOBAL INC COM NPV |  |  | 543 |
|  | &nbsp;&nbsp;&nbsp;RBC BEARINGS INC COM |  |  | 279 |
|  | &nbsp;&nbsp;&nbsp;REGAL REXNORD CORPORATION COM STK |  |  | 338 |
|  | &nbsp;&nbsp;&nbsp;REGIONS FINL CORP NEW COM |  |  | 710 |
|  | &nbsp;&nbsp;&nbsp;REINSURANCE GROUP AMER INC COM NEW STK |  |  | 461 |
|  | &nbsp;&nbsp;&nbsp;RELIANCE INC COM NPV |  |  | 476 |
|  | &nbsp;&nbsp;&nbsp;RENAISSANCE RE HLDGS LTD COM |  |  | 420 |
|  | &nbsp;&nbsp;&nbsp;REPLIGEN CORP COM STK |  |  | 226 |
|  | &nbsp;&nbsp;&nbsp;RESMED INC COM |  |  | 795 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;REVVITY INC |  |  | 451 |
|  | &nbsp;&nbsp;&nbsp;REYNOLDS CONSUMER PRODS INC COM |  |  | 48 |
|  | &nbsp;&nbsp;&nbsp;RH COM |  |  | 155 |
|  | &nbsp;&nbsp;&nbsp;RIVIAN AUTOMOTIVE INC |  |  | 365 |
|  | &nbsp;&nbsp;&nbsp;RLI CORP COM |  |  | 211 |
|  | &nbsp;&nbsp;&nbsp;ROBERT HALF INC COM |  |  | 234 |
|  | &nbsp;&nbsp;&nbsp;ROBINHOOD MKTS INC COM CL A |  |  | 824 |
|  | &nbsp;&nbsp;&nbsp;ROCKET COS INC CL A CL A |  |  | 51 |
|  | &nbsp;&nbsp;&nbsp;ROCKWELL AUTOMATION |  |  | 978 |
|  | &nbsp;&nbsp;&nbsp;ROIVANT SCIENCES LTD COM |  |  | 165 |
|  | &nbsp;&nbsp;&nbsp;ROKU INC COM CL A COM CL A |  |  | 263 |
|  | &nbsp;&nbsp;&nbsp;ROSS STORES INC COM |  |  | 1246 |
|  | &nbsp;&nbsp;&nbsp;ROYAL CARIBBEAN GROUP COM STK |  |  | 1175 |
|  | &nbsp;&nbsp;&nbsp;ROYAL GOLD INC COM STK |  |  | 285 |
|  | &nbsp;&nbsp;&nbsp;ROYALTY PHARMA PLC COM CLASS A |  |  | 327 |
|  | &nbsp;&nbsp;&nbsp;RPM INTL INC |  |  | 398 |
|  | &nbsp;&nbsp;&nbsp;RYDER SYS INC COM |  |  | 214 |
|  | &nbsp;&nbsp;&nbsp;S.W. AIRL CO COM |  |  | 661 |
|  | &nbsp;&nbsp;&nbsp;SAIA INC COM STK |  |  | 165 |
|  | &nbsp;&nbsp;&nbsp;SCHNEIDER NATL INC WIS CL B CL B |  |  | 44 |
|  | &nbsp;&nbsp;&nbsp;SCIENCE APPLICATIONS INTL CORP NEW COM |  |  | 181 |
|  | &nbsp;&nbsp;&nbsp;SCOTTS MIRACLE-GRO CLASS'A'COM NPV |  |  | 93 |
|  | &nbsp;&nbsp;&nbsp;SEABOARD CORP DEL COM |  |  | 19 |
|  | &nbsp;&nbsp;&nbsp;SEALED AIR CORP NEW COM STK |  |  | 153 |
|  | &nbsp;&nbsp;&nbsp;SEAPORT ENTMT GROUP INC COM |  |  | 7 |
|  | &nbsp;&nbsp;&nbsp;SEI INVTS CO COM |  |  | 272 |
|  | &nbsp;&nbsp;&nbsp;SENSATA TECHNOLOGIES B V HOLDING |  |  | 135 |
|  | &nbsp;&nbsp;&nbsp;SENTINELONE INC CL A COM CL A COM |  |  | 171 |
|  | &nbsp;&nbsp;&nbsp;SERVICE CORP INTL COM |  |  | 369 |
|  | &nbsp;&nbsp;&nbsp;SHARKNINJA COM |  |  | 170 |
|  | &nbsp;&nbsp;&nbsp;SILGAN HLDGS INC COM |  |  | 142 |
|  | &nbsp;&nbsp;&nbsp;SIMPSON MFG INC COM |  |  | 210 |
|  | &nbsp;&nbsp;&nbsp;SIRIUS XM HLDGS INC NEW COM |  |  | 161 |
|  | &nbsp;&nbsp;&nbsp;SITEONE LANDSCAPE SUPPLY INC COM |  |  | 122 |
|  | &nbsp;&nbsp;&nbsp;SKECHERS U S A INC CL A |  |  | 266 |
|  | &nbsp;&nbsp;&nbsp;SKYWORKS SOLUTIONS INC COM |  |  | 468 |
|  | &nbsp;&nbsp;&nbsp;SLM CORP COM |  |  | 191 |
|  | &nbsp;&nbsp;&nbsp;SMITH A O CORP COM |  |  | 266 |
|  | &nbsp;&nbsp;&nbsp;SMUCKER J M CO COM NEW |  |  | 373 |
|  | &nbsp;&nbsp;&nbsp;SMURFIT WESTROCK LTD |  |  | 916 |
|  | &nbsp;&nbsp;&nbsp;SNAP-ON INC COM |  |  | 578 |
|  | &nbsp;&nbsp;&nbsp;SOFI TECHNOLOGIES INC COM |  |  | 451 |
|  | &nbsp;&nbsp;&nbsp;SOLVENTUM CORP COM COM |  |  | 301 |
|  | &nbsp;&nbsp;&nbsp;SONOCO PROD CO COM |  |  | 157 |
|  | &nbsp;&nbsp;&nbsp;SOTERA HEALTH CO COM |  |  | 68 |
|  | &nbsp;&nbsp;&nbsp;SPECTRUM BRANDS HLDGS INC COM |  |  | 75 |
|  | &nbsp;&nbsp;&nbsp;SPIRIT AEROSYSTEMS HLDGS INC CL A |  |  | 114 |
|  | &nbsp;&nbsp;&nbsp;SS&C TECHNOLOGIES HLDGS INC COM |  |  | 535 |
|  | &nbsp;&nbsp;&nbsp;STANDARDAERO INC. COM |  |  | 38 |
|  | &nbsp;&nbsp;&nbsp;STANLEY BLACK & DECKER INC COM |  |  | 406 |
|  | &nbsp;&nbsp;&nbsp;STATE STR CORP COM |  |  | 946 |
|  | &nbsp;&nbsp;&nbsp;STEEL DYNAMICS INC COM |  |  | 545 |
|  | &nbsp;&nbsp;&nbsp;STERIS PLC ORD |  |  | 666 |
|  | &nbsp;&nbsp;&nbsp;STIFEL FINL CORP COM |  |  | 347 |
|  | &nbsp;&nbsp;&nbsp;SYNCHRONY FINL COM |  |  | 832 |
|  | &nbsp;&nbsp;&nbsp;SYNOVUS FINL CORP COM NEW COM NEW |  |  | 242 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;SYSCO CORP COM |  |  | 469 |
|  | &nbsp;&nbsp;&nbsp;T ROWE PRICE GROUP INC |  |  | 816 |
|  | &nbsp;&nbsp;&nbsp;TAKE-TWO INTERACTIVE SOFTWARE INC |  |  | 1044 |
|  | &nbsp;&nbsp;&nbsp;TAPESTRY INC COM |  |  | 499 |
|  | &nbsp;&nbsp;&nbsp;TD SYNNEX CORPORATION COM |  |  | 291 |
|  | &nbsp;&nbsp;&nbsp;TECHNIPFMC PLC COM |  |  | 403 |
|  | &nbsp;&nbsp;&nbsp;TELEDYNE TECHNOLOGIES INC COM |  |  | 706 |
|  | &nbsp;&nbsp;&nbsp;TELEFLEX INC COM |  |  | 272 |
|  | &nbsp;&nbsp;&nbsp;TENET HEALTHCARE CORP COM NEW . |  |  | 395 |
|  | &nbsp;&nbsp;&nbsp;TERADYNE INC COM |  |  | 58 |
|  | &nbsp;&nbsp;&nbsp;TETRA TECH INC NEW COM |  |  | 274 |
|  | &nbsp;&nbsp;&nbsp;TEXTRON INC COM |  |  | 470 |
|  | &nbsp;&nbsp;&nbsp;TFS FINL CORP COM STK |  |  | 20 |
|  | &nbsp;&nbsp;&nbsp;THE CAMPBELLS COMPANY |  |  | 264 |
|  | &nbsp;&nbsp;&nbsp;THE COOPER COMPANIES, INC. |  |  | 590 |
|  | &nbsp;&nbsp;&nbsp;THE HARTFORD INSURANCE GROUP INC COM |  |  | 1042 |
|  | &nbsp;&nbsp;&nbsp;THOR INDS INC COM STK |  |  | 160 |
|  | &nbsp;&nbsp;&nbsp;TIMKEN CO COM |  |  | 152 |
|  | &nbsp;&nbsp;&nbsp;TKO GROUP HLDGS INC COM |  |  | 318 |
|  | &nbsp;&nbsp;&nbsp;TOLL BROS INC COM |  |  | 417 |
|  | &nbsp;&nbsp;&nbsp;TOPBUILD CORP COM |  |  | 284 |
|  | &nbsp;&nbsp;&nbsp;TORO CO COM |  |  | 270 |
|  | &nbsp;&nbsp;&nbsp;TPG PARTNERS LLC CL A COM |  |  | 131 |
|  | &nbsp;&nbsp;&nbsp;TRADEWEB MKTS INC CL A CL A |  |  | 303 |
|  | &nbsp;&nbsp;&nbsp;TRANSUNION COM |  |  | 558 |
|  | &nbsp;&nbsp;&nbsp;TRAVEL + LEISURE CO COM |  |  | 109 |
|  | &nbsp;&nbsp;&nbsp;TRIMBLE INC COM TRIMBLE INC |  |  | 566 |
|  | &nbsp;&nbsp;&nbsp;TRIPADVISOR INC COM |  |  | 50 |
|  | &nbsp;&nbsp;&nbsp;TRUMP MEDIA & TECHNOLOGY GROUP CORP |  |  | 31 |
|  | &nbsp;&nbsp;&nbsp;TWILIO INC CL A CL A |  |  | 436 |
|  | &nbsp;&nbsp;&nbsp;TYLER TECHNOLOGIES INC COM STK |  |  | 121 |
|  | &nbsp;&nbsp;&nbsp;TYSON FOODS INC CL A COM (DELAWARE) |  |  | 531 |
|  | &nbsp;&nbsp;&nbsp;UBIQUITI INC COM |  |  | 25 |
|  | &nbsp;&nbsp;&nbsp;UGI CORP NEW COM |  |  | 200 |
|  | &nbsp;&nbsp;&nbsp;U-HAUL HOLDING COMPANY |  |  | 119 |
|  | &nbsp;&nbsp;&nbsp;U-HAUL HOLDING COMPANY |  |  | 10 |
|  | &nbsp;&nbsp;&nbsp;UIPATH INC CL A CL A |  |  | 25 |
|  | &nbsp;&nbsp;&nbsp;ULTA BEAUTY INC |  |  | 91 |
|  | &nbsp;&nbsp;&nbsp;UNDER ARMOR INC CL A |  |  | 53 |
|  | &nbsp;&nbsp;&nbsp;UNDER ARMOUR INC CL C COM |  |  | 45 |
|  | &nbsp;&nbsp;&nbsp;UNITED AIRLINES HOLDINGS INC COM |  |  | 1046 |
|  | &nbsp;&nbsp;&nbsp;UNITED RENTALS INC COM |  |  | 1150 |
|  | &nbsp;&nbsp;&nbsp;UNITED STS STL CORP NEW COM |  |  | 249 |
|  | &nbsp;&nbsp;&nbsp;UNITED THERAPEUTICS CORP DEL COM STK |  |  | 507 |
|  | &nbsp;&nbsp;&nbsp;UNITY SOFTWARE INC COM |  |  | 124 |
|  | &nbsp;&nbsp;&nbsp;UNIVERSAL DISPLAY CORP COM |  |  | 111 |
|  | &nbsp;&nbsp;&nbsp;UNUM GROUP |  |  | 436 |
|  | &nbsp;&nbsp;&nbsp;UNVL HEALTH SERVICES INC CL B COM |  |  | 338 |
|  | &nbsp;&nbsp;&nbsp;US FOODS HLDG CORP COM |  |  | 509 |
|  | &nbsp;&nbsp;&nbsp;UWM HLDGS CORP COM CL A |  |  | 6 |
|  | &nbsp;&nbsp;&nbsp;V F CORP COM |  |  | 247 |
|  | &nbsp;&nbsp;&nbsp;VAIL RESORTS INC COM |  |  | 37 |
|  | &nbsp;&nbsp;&nbsp;VALMONT INDS INC COM |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;VERALTO CORP COM |  |  | 455 |
|  | &nbsp;&nbsp;&nbsp;VERISIGN INC COM |  |  | 531 |
|  | &nbsp;&nbsp;&nbsp;VESTIS CORP COM |  |  | 66 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;VIATRIS INC |  |  | 486 |
|  | &nbsp;&nbsp;&nbsp;VIRTU FINL INC CL A CL A |  |  | 94 |
|  | &nbsp;&nbsp;&nbsp;VONTIER CORP COM |  |  | 180 |
|  | &nbsp;&nbsp;&nbsp;VOYA FINL INC COM |  |  | 223 |
|  | &nbsp;&nbsp;&nbsp;VULCAN MATERIALS CO COM |  |  | 831 |
|  | &nbsp;&nbsp;&nbsp;WABTEC CORP COM |  |  | 1063 |
|  | &nbsp;&nbsp;&nbsp;WALGREENS BOOTS ALLIANCE INC COM |  |  | 220 |
|  | &nbsp;&nbsp;&nbsp;WARNER BROS DISCOVERY INC |  |  | 844 |
|  | &nbsp;&nbsp;&nbsp;WATERS CORP COM |  |  | 281 |
|  | &nbsp;&nbsp;&nbsp;WATSCO INC COM |  |  | 539 |
|  | &nbsp;&nbsp;&nbsp;WAYFAIR INC CL A CL A |  |  | 139 |
|  | &nbsp;&nbsp;&nbsp;WEBSTER FNCL CORP WATERBURY CONN COM |  |  | 310 |
|  | &nbsp;&nbsp;&nbsp;WEC ENERGY GROUP INC COM |  |  | 979 |
|  | &nbsp;&nbsp;&nbsp;WENDYS CO COM |  |  | 46 |
|  | &nbsp;&nbsp;&nbsp;WESCO INTL INC COM |  |  | 250 |
|  | &nbsp;&nbsp;&nbsp;WEST PHARMACEUTICAL SVCS INC COM |  |  | 308 |
|  | &nbsp;&nbsp;&nbsp;WESTERN ALLIANCE BANCORPORATION COM |  |  | 295 |
|  | &nbsp;&nbsp;&nbsp;WESTERN UNION CO |  |  | 97 |
|  | &nbsp;&nbsp;&nbsp;WESTLAKE CORPORATION COM |  |  | 126 |
|  | &nbsp;&nbsp;&nbsp;WESTN DIGITAL CORP COM |  |  | 678 |
|  | &nbsp;&nbsp;&nbsp;WEX INC COM |  |  | 207 |
|  | &nbsp;&nbsp;&nbsp;WHIRLPOOL CORP COM |  |  | 199 |
|  | &nbsp;&nbsp;&nbsp;WHITE MOUNTAINS INSURANCE GROUP COM STOCK |  |  | 160 |
|  | &nbsp;&nbsp;&nbsp;WILLIAMS CO INC COM |  |  | 2167 |
|  | &nbsp;&nbsp;&nbsp;WILLIAMS SONOMA INC COM |  |  | 311 |
|  | &nbsp;&nbsp;&nbsp;WILLIS TOWERS WATSON PLC COM |  |  | 1038 |
|  | &nbsp;&nbsp;&nbsp;WILLSCOT HOLDINGS CORPORATION COM |  |  | 139 |
|  | &nbsp;&nbsp;&nbsp;WINTRUST FINL CORP COM |  |  | 267 |
|  | &nbsp;&nbsp;&nbsp;WOLFSPEED INC COM |  |  | 27 |
|  | &nbsp;&nbsp;&nbsp;WOODWARD INC COM |  |  | 322 |
|  | &nbsp;&nbsp;&nbsp;WYNDHAM HOTELS & RESORTS INC COM |  |  | 229 |
|  | &nbsp;&nbsp;&nbsp;WYNN RESORTS LTD COM |  |  | 268 |
|  | &nbsp;&nbsp;&nbsp;XCEL ENERGY INC COM |  |  | 1277 |
|  | &nbsp;&nbsp;&nbsp;XP INC COM CLASS A |  |  | 143 |
|  | &nbsp;&nbsp;&nbsp;XYLEM INC COM |  |  | 922 |
|  | &nbsp;&nbsp;&nbsp;YETI HLDGS INC COM |  |  | 76 |
|  | &nbsp;&nbsp;&nbsp;YUM BRANDS INC COM |  |  | 766 |
|  | &nbsp;&nbsp;&nbsp;ZEBRA TECHNOLOGIES CORP CL A |  |  | 511 |
|  | &nbsp;&nbsp;&nbsp;ZILLOW GROUP INC COM |  |  | 106 |
|  | &nbsp;&nbsp;&nbsp;ZILLOW GROUP INC COM CLASS C |  |  | 380 |
|  | &nbsp;&nbsp;&nbsp;ZIMMER BIOMET HLDGS INC COM |  |  | 688 |
|  | &nbsp;&nbsp;&nbsp;ZIONS BANCORPORATION N A |  |  | 259 |
|  | &nbsp;&nbsp;&nbsp;ZOOM COMMUNICATIONS INC |  |  | 708 |
|  | &nbsp;&nbsp;&nbsp;ZOOMINFO TECHNOLOGIES INC COM |  |  | 104 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Common stock |  |  | 5066260 |
|  | **Mutual fund** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;PIMCO ALL ASSET FUND |  |  | 108326 |
|  | **REITs** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;1ST INDL RLTY TR INC COM |  |  | 218 |
|  | &nbsp;&nbsp;&nbsp;AGNC INVT CORP COM |  |  | 246 |
|  | &nbsp;&nbsp;&nbsp;AGREE RLTY CORP COM |  |  | 248 |
|  | &nbsp;&nbsp;&nbsp;ALEXANDRIA REAL ESTATE EQUITIES INC COM |  |  | 556 |
|  | &nbsp;&nbsp;&nbsp;AMERICAN HOMES 4 RENT COMMON STOCK |  |  | 415 |
|  | &nbsp;&nbsp;&nbsp;AMERICOLD RLTY TR INC COM |  |  | 200 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **REITs - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;ANNALY CAPITAL MANAGEMENT INC |  |  | 336 |
|  | &nbsp;&nbsp;&nbsp;AVALONBAY CMNTYS REIT |  |  | 1027 |
|  | &nbsp;&nbsp;&nbsp;BRIXMOR PPTY GROUP INC COM |  |  | 274 |
|  | &nbsp;&nbsp;&nbsp;BXP INC |  |  | 384 |
|  | &nbsp;&nbsp;&nbsp;CAMDEN PPTY TR SH BEN INT |  |  | 395 |
|  | &nbsp;&nbsp;&nbsp;COUSINS PPTYS INC |  |  | 162 |
|  | &nbsp;&nbsp;&nbsp;CROWN CASTLE INC COM |  |  | 1299 |
|  | &nbsp;&nbsp;&nbsp;CUBESMART |  |  | 315 |
|  | &nbsp;&nbsp;&nbsp;DIGITAL RLTY TR INC COM |  |  | 1933 |
|  | &nbsp;&nbsp;&nbsp;EASTGROUP PPTYS INC REIT |  |  | 259 |
|  | &nbsp;&nbsp;&nbsp;EPR PPTYS COM SH BEN INT COM SH BEN INT |  |  | 109 |
|  | &nbsp;&nbsp;&nbsp;EQTY LIFESTYLE PPTYS INC REIT |  |  | 414 |
|  | &nbsp;&nbsp;&nbsp;EQTY RESDNTL |  |  | 892 |
|  | &nbsp;&nbsp;&nbsp;ESSEX PPTY TR REIT |  |  | 600 |
|  | &nbsp;&nbsp;&nbsp;EXTRA SPACE STORAGE INC COM |  |  | 1029 |
|  | &nbsp;&nbsp;&nbsp;FEDERAL RLTY INVT TR COM |  |  | 311 |
|  | &nbsp;&nbsp;&nbsp;GAMING & LEISURE PPTYS INC COM |  |  | 412 |
|  | &nbsp;&nbsp;&nbsp;HEALTHCARE REALTY TRUST INC COM |  |  | 196 |
|  | &nbsp;&nbsp;&nbsp;HEALTHPEAK OP LLC |  |  | 466 |
|  | &nbsp;&nbsp;&nbsp;HIGHWOODS PPTYS INC COM |  |  | 105 |
|  | &nbsp;&nbsp;&nbsp;HOST HOTELS & RESORTS INC REIT |  |  | 402 |
|  | &nbsp;&nbsp;&nbsp;INVITATION HOMES INC COM |  |  | 643 |
|  | &nbsp;&nbsp;&nbsp;IRON MTN INC NEW COM |  |  | 432 |
|  | &nbsp;&nbsp;&nbsp;KILROY RLTY CORP COM |  |  | 156 |
|  | &nbsp;&nbsp;&nbsp;KIMCO REALTY CORPORATION |  |  | 507 |
|  | &nbsp;&nbsp;&nbsp;LAMAR ADVERTISING CO NEW CL A CL A |  |  | 261 |
|  | &nbsp;&nbsp;&nbsp;LINEAGE INC COM |  |  | 119 |
|  | &nbsp;&nbsp;&nbsp;MEDICAL PPTYS TR INC COM REIT |  |  | 77 |
|  | &nbsp;&nbsp;&nbsp;MID-AMER APT CMNTYS INC COM |  |  | 591 |
|  | &nbsp;&nbsp;&nbsp;NATIONAL STORAGE AFFILIATES TR COM SHS |  |  | 87 |
|  | &nbsp;&nbsp;&nbsp;NNN REIT INC |  |  | 251 |
|  | &nbsp;&nbsp;&nbsp;OMEGA HEALTHCARE INVS INC REIT |  |  | 336 |
|  | &nbsp;&nbsp;&nbsp;PARK HOTELS & RESORTS INC COM |  |  | 94 |
|  | &nbsp;&nbsp;&nbsp;RAYONIER INC REIT |  |  | 132 |
|  | &nbsp;&nbsp;&nbsp;REALTY INCOME CORP COM |  |  | 1531 |
|  | &nbsp;&nbsp;&nbsp;REGENCY CTRS CORP COM |  |  | 439 |
|  | &nbsp;&nbsp;&nbsp;REXFORD INDL RLTY INC COM |  |  | 280 |
|  | &nbsp;&nbsp;&nbsp;RITHM CAPITAL CORP |  |  | 184 |
|  | &nbsp;&nbsp;&nbsp;SBA COMMUNICATIONS CORP |  |  | 720 |
|  | &nbsp;&nbsp;&nbsp;SIMON PROPERTY GROUP INC COM |  |  | 1364 |
|  | &nbsp;&nbsp;&nbsp;STAG INDL INC COM |  |  | 201 |
|  | &nbsp;&nbsp;&nbsp;STARWOOD PROPERTY TRUST INC COM REIT |  |  | 195 |
|  | &nbsp;&nbsp;&nbsp;SUN COMMUNITIES INC COM |  |  | 499 |
|  | &nbsp;&nbsp;&nbsp;UDR INC COM STK |  |  | 469 |
|  | &nbsp;&nbsp;&nbsp;VENTAS INC REIT |  |  | 811 |
|  | &nbsp;&nbsp;&nbsp;VICI PPTYS INC COM |  |  | 1000 |
|  | &nbsp;&nbsp;&nbsp;VORNADO RLTY TR COM |  |  | 242 |
|  | &nbsp;&nbsp;&nbsp;W P CAREY INC COM |  |  | 389 |
|  | &nbsp;&nbsp;&nbsp;WEYERHAEUSER CO COM |  |  | 675 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total REITs |  |  | 25888 |
|  | **Collective trust funds** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND |  |  | 103319 |
|  | &nbsp;&nbsp;&nbsp;CAPITAL GROUP EUROPACIFIC GROWTH TRUST |  |  | 349968 |
|  | &nbsp;&nbsp;&nbsp;CAPITAL GROUP GROWTH FUND OF AMERICA TRUST |  |  | 1349967 |
|  | &nbsp;&nbsp;&nbsp;CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST |  |  | 396199 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Collective trust funds - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;GW&K SMALL-MID CAP CORE EQUITY FUND |  |  | 171932 |
| &nbsp;&nbsp;\* | &nbsp;&nbsp;&nbsp;NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND |  |  | 154276 |
| &nbsp;&nbsp;\* | &nbsp;&nbsp;&nbsp;NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND |  |  | 12293 |
|  | &nbsp;&nbsp;&nbsp;PIMCO TOTAL RETURN FUND |  |  | 212742 |
|  | &nbsp;&nbsp;&nbsp;SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K |  |  | 865253 |
|  | &nbsp;&nbsp;&nbsp;SSGA S&P 500 INDEX FUND CLASS K |  |  | 2317737 |
|  | &nbsp;&nbsp;&nbsp;SSGA U.S. BOND INDEX FUND CLASS K |  |  | 156209 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2020 |  |  | 196946 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2025 |  |  | 405218 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2030 |  |  | 571713 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2035 |  |  | 563164 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2040 |  |  | 476607 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2045 |  |  | 422489 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2050 |  |  | 345438 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2055 |  |  | 228773 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2060 |  |  | 130750 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT 2065 |  |  | 41540 |
|  | &nbsp;&nbsp;&nbsp;SSGA TARGET RETIREMENT INCOME |  |  | 120357 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Collective trust funds |  |  | 9592890 |
|  | **Futures contracts** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;FUT MAR 25 IMMEMINI MDCP |  |  | (629) |
|  | &nbsp;&nbsp;&nbsp;FUT MAR 25 IMMEMINI MDCP |  |  | 629 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Futures contracts |  |  |  |
|  | **Corporate debt** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;AMERICAN HONDA FIN CORP FLTG 02-12-2025 |  |  | 6602 |
|  | &nbsp;&nbsp;&nbsp;AVOLON HLDGS FDG 2.875% DUE 02-15-2025 |  |  | 5881 |
|  | &nbsp;&nbsp;&nbsp;BANK OF AMERICA CORPORATION MTN 3.384% DUE 04-02-2026 |  |  | 1893 |
|  | &nbsp;&nbsp;&nbsp;BARCLAYS PLC 3.65% DUE 03-16-2025 |  |  | 2493 |
|  | &nbsp;&nbsp;&nbsp;BOEING CO 2.25% DUE 06-15-2026 |  |  | 384 |
|  | &nbsp;&nbsp;&nbsp;BOEING CO FIXED 2.196% DUE 02-04-2026 |  |  | 970 |
|  | &nbsp;&nbsp;&nbsp;CARLYLE GLOBAL MARKET STRATEGI 14/08/2030 0% 08-14-2030 |  |  | 349 |
|  | &nbsp;&nbsp;&nbsp;CARMAX AUTO OWNER 3.49% DUE 02-16-2027 |  |  | 824 |
|  | &nbsp;&nbsp;&nbsp;CARMAX AUTO OWNER TRUST SER 22-4 CL A3 5.34% DUE 08-16-2027 REG |  |  | 2292 |
|  | &nbsp;&nbsp;&nbsp;CHASE AUTO OWNER TR 2023-A ASSET BACKED NT CL A-2 144A 5.9% 03-25-2027 |  |  | 1055 |
|  | &nbsp;&nbsp;&nbsp;CHASE AUTO OWNER TR 2024-5 NT CL A-2 144A 4.4% 11-26-2027 |  |  | 1298 |
|  | &nbsp;&nbsp;&nbsp;CITIGROUP INC 3.106% DUE 04-08-2026 |  |  | 9653 |
|  | &nbsp;&nbsp;&nbsp;COLUMBIA / HCA 7.69% DUE 06-15-2025 |  |  | 2023 |
|  | &nbsp;&nbsp;&nbsp;CVS CAREMARK CORP DISC COML PAPER 4/2 YRS 1&2 01-31-2025 |  |  | 4081 |
|  | &nbsp;&nbsp;&nbsp;DEUTSCHE BK AG N Y FLTG RT 2.129% DUE 11-24-2026 |  |  | 1949 |
|  | &nbsp;&nbsp;&nbsp;DLLAD 2024-1 LLC 5.5% DUE 08-20-2027 |  |  | 2006 |
|  | &nbsp;&nbsp;&nbsp;ELEVATION CLO FLTG RT 0% DUE 07-25-2034 |  |  | 1500 |
|  | &nbsp;&nbsp;&nbsp;ELLINGTON FINL MTG TR 2022-1 MTG PASS THRU CTF CL A-1 2.206% 01-25-2067 |  |  | 2015 |
|  | &nbsp;&nbsp;&nbsp;FORD CR AUTO LEASE TR 2023-B FLTG RT SR 23-B CL A2B 02-15-2026 |  |  | 463 |
|  | &nbsp;&nbsp;&nbsp;FORD CR AUTO LEASE TR 2024-B SR 24-B CL A2B FLTG RT 02-15-2027 |  |  | 2889 |
|  | &nbsp;&nbsp;&nbsp;FORD CR AUTO OWNER 5.4% DUE 04-15-2027 |  |  | 7033 |
|  | &nbsp;&nbsp;&nbsp;FORD CREDIT AUTO LEASE TRUST SER 23-A CL A3 4.94% 03-15-2026 |  |  | 920 |
|  | &nbsp;&nbsp;&nbsp;FORD MTR CR CO LLC 4.134% DUE 08-04-2025 |  |  | 3593 |
|  | &nbsp;&nbsp;&nbsp;FORD MTR CR CO LLC 4.687% 06-09-2025 |  |  | 3292 |
|  | &nbsp;&nbsp;&nbsp;FORD MTR CR CO LLC 5.125% DUE 06-16-2025 |  |  | 1499 |
|  | &nbsp;&nbsp;&nbsp;GENERAL MTRS FINL CO INC CORP 2.9% 02-26-2025 |  |  | 3986 |
|  | &nbsp;&nbsp;&nbsp;GEORGIA PWR CO FLTG RT 05-08-2025 |  |  | 3006 |
|  | &nbsp;&nbsp;&nbsp;GOLDMAN SACHS FLTG RT 5.11322% DUE 12-09-2026 |  |  | 3407 |
|  | &nbsp;&nbsp;&nbsp;GS MTG BACKED SECS 5% DUE 01-25-2052 |  |  | 2272 |
|  | &nbsp;&nbsp;&nbsp;HARLEY DAVIDSON 3.5% DUE 07-28-2025 |  |  | 1698 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Corporate debt - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;HCA INC 5.25% DUE 04-15-2025 |  |  | 1502 |
|  | &nbsp;&nbsp;&nbsp;HCA INC 5.375% DUE 02-01-2025 |  |  | 1670 |
|  | &nbsp;&nbsp;&nbsp;HCA INC 5.875% DUE 02-15-2026 |  |  | 603 |
|  | &nbsp;&nbsp;&nbsp;HSBC HLDGS PLC FLTG RT 2.999% DUE 03-10-2026 |  |  | 797 |
|  | &nbsp;&nbsp;&nbsp;HSBC HLDGS PLC FLTG RT 4.292% DUE 09-12-2026 |  |  | 1991 |
|  | &nbsp;&nbsp;&nbsp;LLOYDS BANKING GROUP 3.511% DUE 03-18-2026/03-18-2025 BEO |  |  | 299 |
|  | &nbsp;&nbsp;&nbsp;MERCEDES-BENZ AUTO LEASE TRUST SR 24-B CL A2B FLTG RT 12-15-2026 |  |  | 4001 |
|  | &nbsp;&nbsp;&nbsp;MFA 2020-NQM2 TR 1.381% DUE 04-25-2065 |  |  | 292 |
|  | &nbsp;&nbsp;&nbsp;MITSUBISHI UFJ FINL GROUP INC 3.837% 04-17-2026 |  |  | 4041 |
|  | &nbsp;&nbsp;&nbsp;MITSUBISHI UFJ FINL GROUP INC 5.541% DUE04-17-2026 |  |  | 801 |
|  | &nbsp;&nbsp;&nbsp;MIZUHO FINL GROUP INC FLTG 05-22-2026 |  |  | 2205 |
|  | &nbsp;&nbsp;&nbsp;MORGAN STANLEY BANK FRN 10-15-2027 |  |  | 6006 |
|  | &nbsp;&nbsp;&nbsp;NAVIENT PRIVATE ED LN TR 2020-I 5.43366%04-15-2069 |  |  | 1154 |
|  | &nbsp;&nbsp;&nbsp;NEUBERGER BERMAN CLO LTD 20/04/2031 1.29400002956% 04-21-2031 |  |  | 3829 |
|  | &nbsp;&nbsp;&nbsp;NOMURA HLDGS INC 2.648% 01-16-2025 |  |  | 6094 |
|  | &nbsp;&nbsp;&nbsp;NXP B V / NXP FDG LLC / NXP USA INC SR NT 2.7% 05-01-2025 |  |  | 298 |
|  | &nbsp;&nbsp;&nbsp;OBX 2022-NQM1 TR MTG BACKED NT CL A-1 144A 2.30500006676% 11-25-2061 |  |  | 1817 |
|  | &nbsp;&nbsp;&nbsp;OBX 2022-NQM2 TR VAR RT 2.783% DUE 01-25-2062 |  |  | 606 |
|  | &nbsp;&nbsp;&nbsp;ONEOK INC 4.25% 09-24-2027 |  |  | 1183 |
|  | &nbsp;&nbsp;&nbsp;PAC GAS & ELEC CO FIXED 3.45% DUE 07-01-2025 |  |  | 893 |
|  | &nbsp;&nbsp;&nbsp;PAC GAS & ELEC CO FLTG RT 5.289197% DUE 09-04-2025 |  |  | 4908 |
|  | &nbsp;&nbsp;&nbsp;PNC BANK NA FLTG 01-15-2027 |  |  | 3401 |
|  | &nbsp;&nbsp;&nbsp;PVTPL ABN AMRO BANK NV 6.575% 10-13-2026 |  |  | 4042 |
|  | &nbsp;&nbsp;&nbsp;PVTPL ARES XXVII CLO LTD SR 13 2A CL A-R3 FLTG 10-28-2034 |  |  | 2000 |
|  | &nbsp;&nbsp;&nbsp;PVTPL ATLANTIC AVE 2024-3 LTD SR 24-3A CL A FLTG 01-20-2035 |  |  | 2000 |
|  | &nbsp;&nbsp;&nbsp;PVTPL BAIN CAPITAL CREDIT CLO LIMITED SR 20-2A CL ARR FLTG RT 07-19-2034 |  |  | 3105 |
|  | &nbsp;&nbsp;&nbsp;PVTPL BAIN CAPITAL CREDIT CLO LTD SR 21-3A AR FLTG RT 07-24-2034 |  |  | 250 |
|  | &nbsp;&nbsp;&nbsp;PVTPL BANK OF AMERICA AUTO TRUST SER 23-2A CL A2 5.85% 08-17-2026 |  |  | 2283 |
|  | &nbsp;&nbsp;&nbsp;PVTPL BANQUE FED CRED MUTUEL FLTG RT 01-23-2027 |  |  | 1411 |
|  | &nbsp;&nbsp;&nbsp;PVTPL BAYER US FIN II LLC 4.25% 12-15-2025 |  |  | 4966 |
|  | &nbsp;&nbsp;&nbsp;PVTPL CITIZENS AUTO RECEIVABLES TRUST SER 24-2 CL A2B FLTG RT 11-16-2026 |  |  | 1766 |
|  | &nbsp;&nbsp;&nbsp;PVTPL CMO AREIT 2021-CRE5 LTD/AREIT AREIT 2021-C SR NT CL A VAR RT 07-17-2026 |  |  | 342 |
|  | &nbsp;&nbsp;&nbsp;PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066 |  |  | 1691 |
|  | &nbsp;&nbsp;&nbsp;PVTPL CQS US CLO LTD SER 21-1A CL AR FLTG 01-20-2035 |  |  | 2003 |
|  | &nbsp;&nbsp;&nbsp;PVTPL DLLMT 2024-1 LLC NT CL A-1 144A 5.353% DUE 08-20-2025 BEO |  |  | 899 |
|  | &nbsp;&nbsp;&nbsp;PVTPL ELECTRICITE DE FRANCE SA 3.625% 10-13-2025 |  |  | 1486 |
|  | &nbsp;&nbsp;&nbsp;PVTPL ENTERPRISE FLEET FINANCING LLC SR 24-2 CL A1 5.613% 05-20-2025 |  |  | 661 |
|  | &nbsp;&nbsp;&nbsp;PVTPL GOLUB CAP PARTNERS STATIC 2024-1 LTD/G SR 24-1A CL A-1 VAR RT 04-20-2033 |  |  | 2417 |
|  | &nbsp;&nbsp;&nbsp;PVTPL GPMT 2021-FL3 LTD/GPMT 2021-FL3 LLC SR SECD NT CL A FLTG 07-16-2035 |  |  | 750 |
|  | &nbsp;&nbsp;&nbsp;PVTPL HYUNDAI AUTO LEASE SECURITIZATION TR 202 FLTG RT SR 23-C CL A2B 03-16-2026 |  |  | 2024 |
|  | &nbsp;&nbsp;&nbsp;PVTPL KKR CLO 9 LTD / KKR CLO 9 LLC 15/07/2030 VAR RT DUE 07-15-2030 BEO |  |  | 886 |
|  | &nbsp;&nbsp;&nbsp;PVTPL LCM 31 LTD SR SECD NT CL A-R FLTG 07-20-2034 |  |  | 1103 |
|  | &nbsp;&nbsp;&nbsp;PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE LO SR 20-FL4 CL A VAR RT DUE 11-15-2035 |  |  | 626 |
|  | &nbsp;&nbsp;&nbsp;PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE CO SER 21-FL7 CL A FLTG RT DUE 10-18-2036 |  |  | 2929 |
|  | &nbsp;&nbsp;&nbsp;PVTPL NAVIENT PRIVATE ED REFI LN TR 2021-G CL A 1.58% DUE 04-15-2070 BEO |  |  | 1275 |
|  | &nbsp;&nbsp;&nbsp;PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069 |  |  | 615 |
|  | &nbsp;&nbsp;&nbsp;PVTPL NAVIENT STUDENT LN TR 2014-1 SR 22-A CL A 2.23% 07-15-2070 |  |  | 957 |
|  | &nbsp;&nbsp;&nbsp;PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO |  |  | 1113 |
|  | &nbsp;&nbsp;&nbsp;PVTPL NISSAN MTR ACCEP CO LLC NT 1.85% 09-16-2026 |  |  | 846 |
|  | &nbsp;&nbsp;&nbsp;PVTPL OCTAGON INVT PARTNERS XXI LTD/OCTAGON SR SECD NT 02-14-2031 |  |  | 2283 |
|  | &nbsp;&nbsp;&nbsp;PVTPL PALMER SQUARE LN FDG 2021-3 LTD/SR SECD NT CL A-1 FLTG 5.04257% 07-20-2029 |  |  | 407 |
|  | &nbsp;&nbsp;&nbsp;PVTPL PALMER SQUARE LOAN FUNDING LTD SER 21-4A CL A1 FLTG RT 10-15-2029 BEO |  |  | 561 |
|  | &nbsp;&nbsp;&nbsp;PVTPL REGATTA XVI FUNDING LTD SR 19-2A CL A1R FLTG RT 01-15-2033 |  |  | 3919 |
|  | &nbsp;&nbsp;&nbsp;PVTPL SBA TOWER TR 4.831% 10-15-2029 |  |  | 1350 |
|  | &nbsp;&nbsp;&nbsp;PVTPL SOCIETE GENERALE FLTG 01-21-2026 |  |  | 3001 |
|  | &nbsp;&nbsp;&nbsp;PVTPL SOUND PT CLO XVI LTD/SOUND PT CLO XVI VAR RT DUE 07-25-2030 BEO |  |  | 292 |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Corporate debt - continued** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;PVTPL SYMPHONY CLO LTD SR 20-22A CL A1ARFLTG RT 04-18-2033 |  |  | 1000 |
|  | &nbsp;&nbsp;&nbsp;PVTPL TOWD POINT MORTGAGE TRUST SER 21-1 CL A1 VAR 11-25-2061 |  |  | 1503 |
|  | &nbsp;&nbsp;&nbsp;PVTPL TOYOTA LEASE OWNER TRUST SR 24-B CL A2B FLTG RT 02-22-2027 |  |  | 1701 |
|  | &nbsp;&nbsp;&nbsp;PVTPL TRILLIUM CR CARD TR II SR 23-3A CLA VAR RT DUE 08-26-2028 BEO |  |  | 3210 |
|  | &nbsp;&nbsp;&nbsp;PVTPL VENTURE CLO LTD SR 17-28A CL A2R VAR RT 07-20-2030 |  |  | 1825 |
|  | &nbsp;&nbsp;&nbsp;PVTPL VMC FIN 2021-FL4 LLC SR SECD NT CLA 144A FLTG RATE VAR RT DUE 06-16-2036 |  |  | 96 |
|  | &nbsp;&nbsp;&nbsp;PVTPL VOYA CLO LTD SR 19-2A CL AR FLTG 07-20-2032 |  |  | 1200 |
|  | &nbsp;&nbsp;&nbsp;ROGERS COMMUNICATIONS INC SR NT 2.95% 03-15-2025 |  |  | 2984 |
|  | &nbsp;&nbsp;&nbsp;SABINE PASS 5.625% DUE 03-01-2025 |  |  | 552 |
|  | &nbsp;&nbsp;&nbsp;SARANAC CLO VI LTD / SARANAC CLO VI 5.69859% 08-13-2031 |  |  | 878 |
|  | &nbsp;&nbsp;&nbsp;SOCIETE GENERALE 2.625% DUE 01-22-2025 |  |  | 3995 |
|  | &nbsp;&nbsp;&nbsp;SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046 |  |  | 776 |
|  | &nbsp;&nbsp;&nbsp;SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-06-2025 |  |  | 7994 |
|  | &nbsp;&nbsp;&nbsp;T-MOBILE USA INC 3.5% 04-15-2025 |  |  | 2986 |
|  | &nbsp;&nbsp;&nbsp;TOYOTA LEASE OWNER FLTG RT 4.89867% DUE 04-20-2026 |  |  | 1198 |
|  | &nbsp;&nbsp;&nbsp;VMWARE INC FIXED 4.5% DUE 05-15-2025 |  |  | 6990 |
|  | &nbsp;&nbsp;&nbsp;VOLKSWAGEN AUTO FLTG RT 4.91867% DUE 01-20-2026 |  |  | 736 |
|  | &nbsp;&nbsp;&nbsp;VOLKSWAGEN GROUP AMER FIN LLC FLTG 03-20-2026 |  |  | 3299 |
|  | &nbsp;&nbsp;&nbsp;WELLS FARGO & CO MEDIUM TERM SR NTS BOOKVAR RT DUE 04-25-2026/04-25-2025 |  |  | 2308 |
|  | &nbsp;&nbsp;&nbsp;WELLS FARGO & COMPANY 3.908% 04-25-2026 |  |  | 2492 |
|  | &nbsp;&nbsp;&nbsp;WORLD OMNI FLTG RT 4.77867% DUE 02-16-2027 |  |  | 1693 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Corporate debt |  |  | 235392 |
|  | **Government debt** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;FANNIE MAE POOL #AM9004 2.8% 06-01-2025 |  |  | 1741 |
|  | &nbsp;&nbsp;&nbsp;FANNIE MAE SR 24-100 CL FA 5.73164% 06-25-2054 |  |  | 1995 |
|  | &nbsp;&nbsp;&nbsp;FANNIE MAE SR 24-103 CL FC FLTG RT 01-25-2055 |  |  | 997 |
|  | &nbsp;&nbsp;&nbsp;FANNIE MAE SR 24-90 CL FB FLTG RT 11-25-2053 |  |  | 2873 |
|  | &nbsp;&nbsp;&nbsp;FANNIE MAE TR SR 24-95 CL KF FLTG 12-25-2054 |  |  | 1468 |
|  | &nbsp;&nbsp;&nbsp;FEDERAL HOME LN MTG CORP SER 5442 CL FB FLTG 08-25-2054 |  |  | 2918 |
|  | &nbsp;&nbsp;&nbsp;FHLMC SR 5480 CL FG FLTG RT 12-25-2054 |  |  | 981 |
|  | &nbsp;&nbsp;&nbsp;FNMA FLTG RT 11-05-2027 |  |  | 6001 |
|  | &nbsp;&nbsp;&nbsp;FNMA REMIC TR 2024-101 CL-FB VAR 5.45201% 01-25-2055 |  |  | 1993 |
|  | &nbsp;&nbsp;&nbsp;FNMA REMIC TR 2024-104 CL-FA VAR 5.40201% 01-25-2055 |  |  | 994 |
|  | &nbsp;&nbsp;&nbsp;FREDDIE MAC MULTICLASS SR 5410 CL FB FLTG RT 05-25-2054 |  |  | 1420 |
|  | &nbsp;&nbsp;&nbsp;FREDDIE MAC SR 5484 CL FA FLTG RT 12-25-2054 |  |  | 2049 |
|  | &nbsp;&nbsp;&nbsp;GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066 |  |  | 325 |
|  | &nbsp;&nbsp;&nbsp;GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066 |  |  | 737 |
|  | &nbsp;&nbsp;&nbsp;GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066 |  |  | 60 |
|  | &nbsp;&nbsp;&nbsp;GNMA SR 23-H22 CL FB FLTG RT 09-20-2073 |  |  | 3013 |
|  | &nbsp;&nbsp;&nbsp;UNITED STATES TREAS NTS 4.25% 11-30-2026 |  |  | 102272 |
|  | &nbsp;&nbsp;&nbsp;US TREASURY N/B 3.625% 08-31-2029 |  |  | 14038 |
|  | &nbsp;&nbsp;&nbsp;US TREASURY N/B 4.125% 11-30-2029 |  |  | 8897 |
|  | &nbsp;&nbsp;&nbsp;UNITED STATES TREASURY BILLS 0% 03-27-2025 |  |  | 40 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Government debt |  |  | 154812 |
|  | **Private 40-Act mutual funds** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;PIMCO SHORT-TERM FLOATING NAV PORTFOLIO II |  |  | 393035 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Private 40-Act mutual funds |  |  |  |

---

**Abbott Laboratories Stock Retirement Plan**

**EIN: 36-0698440, Plan Number: 334**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  |  | &nbsp;&nbsp;Interest rates 3.25% to 9.75% | &nbsp;&nbsp;Interest rates 3.25% to 9.75% |  |
| &nbsp;&nbsp;\* | **Loans to participants** | &nbsp;&nbsp;Maturing 2025 through 2047 | &nbsp;&nbsp;Maturing 2025 through 2047 | 100167 |
|  |  |  |  | $15676770 |

---

\*Represents a party-in-interest transaction.

\*\*Cost information omitted as all investments are fully participant directed.

**FINANCIAL STATEMENTS AND**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

**ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)** 

**DECEMBER 31, 2024 and 2023**

**C O N T E N T S**

---

| | |
|:---|:---|
|  | **Page** |
| [REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM](#sp4_001) | [3](#sp4_001) |
| FINANCIAL STATEMENTS |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS](#sp4_002) | [5](#sp4_002) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS](#sp4_004) | [6](#sp4_004) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[NOTES TO FINANCIAL STATEMENTS](#sp4_003) | [7](#sp4_003) |
| [SUPPLEMENTAL SCHEDULE](#sp4_005) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)](#sp4_006) | [17](#sp4_006) |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

Plan Administrator and Plan Participants<br> Abbott Laboratories Stock Retirement Plan (Puerto Rico)

**Opinion on the financial statements**

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the "Plan") as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

**Basis for opinion**

These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on the Plan's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Supplemental information**

The schedule of assets (held at end of year) as of December 31, 2024 ("supplemental information") has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan's auditor since 2014.

Chicago, Illinois<br> June 20, 2025

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS**

**December 31, 2024 and 2023**

**(Dollars in thousands)**

------

---

| | | |
|:---|:---|:---|
|  | 2024 | 2023 |
| Assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $27 | $- |
| &nbsp;&nbsp;&nbsp;Investments, at fair value | 237222 | 217659 |
| &nbsp;&nbsp;&nbsp;Notes receivable from participants | 5803 | 5172 |
| &nbsp;&nbsp;&nbsp;Due from brokers | 22 | 16 |
| &nbsp;&nbsp;&nbsp;Accrued interest income | 225 | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | 243299 | 222901 |
| Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Cash overdraft |  | 21 |
| &nbsp;&nbsp;&nbsp;Accrued expenses |  | 1 |
| &nbsp;&nbsp;&nbsp;Due to brokers | - | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | - | 25 |
| **NET ASSETS AVAILABLE FOR BENEFITS** | $243299 | $222876 |

---

The accompanying notes are an integral part of these statements.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS**

**Year ended December 31, 2024**

**(Dollars in thousands)**

------

---

| | |
|:---|:---|
| Additions |  |
| &nbsp;&nbsp;&nbsp;Contributions |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employer | $2518 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participant | 5173 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total contributions | 7691 |
| &nbsp;&nbsp;&nbsp;Investment income |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net appreciation in fair value of investments | 20681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest and dividends | 5529 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment income | 26210 |
| &nbsp;&nbsp;&nbsp;Interest income on notes receivable from participants | 355 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net additions | 34256 |
| Deductions |  |
| &nbsp;&nbsp;&nbsp;Benefits paid to participants | 13810 |
| &nbsp;&nbsp;&nbsp;Other expenses | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deductions | 13833 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET INCREASE** | 20423 |
| Net assets available for benefits |  |
| &nbsp;&nbsp;&nbsp;Beginning of year | 222876 |
| &nbsp;&nbsp;&nbsp;End of year | $243299 |

---

The accompanying notes are an integral part of this statement.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS**

**December 31, 2024 and 2023**

------

**NOTE A - DESCRIPTION OF THE PLAN**

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the "Plan") provides only general information. Participants should refer to the Plan document for a more complete description of the Plan's provisions.

***General***

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories ("Abbott") separating into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The Plan covers employees of Abbott's selected subsidiaries and affiliates in Puerto Rico (the "Company").

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure ("Abbott Green" employees).

The Plan's sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company ("Custodian") and Banco Popular de Puerto Rico ("Trustee") serve as the Plan's custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA").

***Contributions and Vesting***

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the "Committee") may direct the Trustee to establish investment options of the Committee's choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE A - DESCRIPTION OF THE PLAN - Continued**

***Contributions and Vesting - Continued***

Employer matching contributions to the Plan are made each payroll period based on the participating employees' eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2024 was 5% of the participant's eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant's investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan's default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

---

| | |
|:---|:---|
| Service | Vesting percentage |
| Less than two years | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% |
| Two years or more | 100% |

---

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee's termination date. Forfeitures are used to (1) restore any forfeitures of participants who

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE A - DESCRIPTION OF THE PLAN - Continued**

***Contributions and Vesting - Continued***

returned to service with the Company within a given period of time, (2) pay Plan expenses as deemed appropriate by the administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2024, approximately $106,700 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $109,300 and $118,200 were available at the end of 2024 and 2023, respectively.

***Distributions and In-Service Withdrawals***

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Interest, dividends and other earnings will continue to accrue on any deferred amounts prior to distribution.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant's account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

***Notes Receivable from Participants***

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee's anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee's anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Accounting***

The financial statements have been prepared using the accrual basis of accounting.

***Use of Estimates***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

***Investment Valuation***

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

<u>Common stock and mutual funds</u> - Valued at the published market price per share or unit multiplied by the number of shares or units held.

<u>Collective trust funds and Private 40-Act mutual funds</u> - Valued at the net asset value ("NAV") provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

The following tables summarize the basis used to measure investments at fair value at December 31, 2024 and 2023 (dollars in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2024** | Quoted<br> Prices in <br> Active <br> Markets | Significant <br> Other <br> Observable <br> Inputs | Significant<br> Unobservable <br> Inputs | Measured at<br> NAV | Total |
| Common stock | $96512 | $- | $- | $- | $96512 |
| Mutual funds | 48681 |  |  |  | 48681 |
| Collective trust funds | - | - | - | 92029 | 92029 |
| &nbsp;&nbsp;&nbsp;Total investments, at fair value | $145193 | $- | $- | $92029 | $237222 |

---

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation - Continued***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | Basis of Fair Value Measurement | |
| **2023** | Quoted<br> Prices in<br> Active<br> Markets | Significant<br> Other<br> Observable<br> Inputs | Significant<br> Unobservable<br> Inputs | Measured at <br> NAV | Total |
| Common stock | $95946 | $- | $- | $- | $95946 |
| Mutual funds | 44900 |  |  |  | 44900 |
| Collective trust funds | - | - | - | 76813 | 76813 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investments, at fair value | $140846 | $- | $- | $76813 | $217659 |

---

Participants are permitted to make redemptions from the Plan's investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2024 and 2023. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | 2024 | 2024 | 2024 | 2024 |
|  | Fair value<br>(NAV) | Redemption<br>frequency | Redemption<br>notice period |<br>Restrictions |
| Funds filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Collective trusts | $92029 | Daily | 0 - 5 days |  |

---

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Investment Valuation - Continued***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | 2023 | 2023 | 2023 | 2023 |
|  | Fair value<br> (NAV) | Redemption<br> frequency | Redemption <br> notice period | Restrictions |
| Funds filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Collective trusts | $76813 | Daily | 0 - 5 days |  |
| Funds not filing as direct filing entity: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Private 40-Act mutual funds |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities | 293 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate fixed income | 556 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inflation-indexed bonds | 80 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International fixed income | 227 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mortgage-related securities | 301 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Municipal fixed income | 25 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term fixed income | 96 | Daily |  | Yes (a) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. Government securities | 405 | Daily |  | Yes (a) |
|  | 1983 |  |  |  |
|  | $78796 |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or
1% of the respective fund's net assets during any 90-day period for any one shareholder. In consideration of the best interests
of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount
in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares
would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request,
but may take up to seven days.

***Notes Receivable from Participants***

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

***Income Recognition***

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued**

***Contributions***

Contributions from Plan participants and the matching contributions from the employer are recorded in the year in which the employee contributions are withheld from compensation.

***Administrative Expenses***

Participants are charged transaction fees for loan processing, which are included in other expenses and commissions on purchases and sales of Abbott shares and sales of AbbVie shares, which are included in net appreciation in fair value of investments. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund and are also included in net appreciation in fair value of investments. The Company pays other record-keeping and administration fees, where applicable. Expenses paid by the Company are excluded from these financial statements.

***Payment of Benefits***

Benefits are recorded when paid.

**NOTE C - INVESTMENTS**

Distributions of Abbott common shares and conversions of participants' common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2024 and 2023 is presented below:

---

| | | |
|:---|:---|:---|
|  | 2024 | 2023 |
| Abbott common shares, 553,452 and 581,107 shares, respectively (dollars in thousands) | $62601 | $63962 |
| Market value per share | $113.11 | $110.07 |

---

**NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS**

The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan's assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2024, the Plan received $1,243,000 in common stock dividends from Abbott.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS - Continued**

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

**NOTE E - PLAN TERMINATION**

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants' account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant's share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

**NOTE F - TAX STATUS**

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**NOTES TO FINANCIAL STATEMENTS - CONTINUED**

**December 31, 2024 and 2023**

------

**NOTE G - RISKS AND UNCERTAINTIES**

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

**NOTE H – SUBSEQUENT EVENTS**

Management of the Plan has evaluated subsequent events from December 31, 2024 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

Effective January 1, 2025, forfeitures will be used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, and (2) reduce future employer contributions if terminated participants do not return to service within the given period of time.

SUPPLEMENTAL SCHEDULE

**Abbott Laboratories Stock Retirement Plan (Puerto Rico)**

**EIN: 98-1051267, Plan Number: 002**

**SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)**

**December 31, 2024**

**(Dollars in thousands)**

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | (c) Description |  | |
|  |  | of investment |  | |
|  |  | including |  | |
|  |  | maturity date & |  | (e) Current |
| (a) | (b) Identity of issue, borrower, lessor, or similar party | range of interest | (d) Cost <sup>\*\*</sup> | value |
|  | **Common stock - employer securities** |  |  |  |
| \* | &nbsp;&nbsp;&nbsp;Abbott Laboratories, common shares |  |  | $62601 |
|  | **Common stock** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;AbbVie Inc., common stock |  |  | 33911 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Common stock |  |  | 96512 |
|  | **Mutual funds** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;American Funds EuroPacific Growth Fund |  |  | 5702 |
|  | &nbsp;&nbsp;&nbsp;American Funds The Growth Fund of America Fund |  |  | 19845 |
|  | &nbsp;&nbsp;&nbsp;American Funds Washington Mutual Investors Fund |  |  | 4837 |
|  | &nbsp;&nbsp;&nbsp;PIMCO All Asset Fund |  |  | 2582 |
|  | &nbsp;&nbsp;&nbsp;PIMCO Short Asset Investment Fund |  |  | 11815 |
|  | &nbsp;&nbsp;&nbsp;Vanguard Mid-Cap Value Index Fund Admiral |  |  | 3900 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Mutual funds |  |  | 48681 |
|  | **Collective trust funds** |  |  |  |
|  | &nbsp;&nbsp;&nbsp;Blackrock International Opportunities Fund |  |  | 1982 |
|  | &nbsp;&nbsp;&nbsp;GW&K Small-Mid Cap Core Equity Fund |  |  | 3206 |
| \* | &nbsp;&nbsp;&nbsp;Northern Trust Collective ACWI ex-U.S. Index Fund |  |  | 897 |
| \* | &nbsp;&nbsp;&nbsp;Northern Trust Collective Short Term Investment Fund |  |  | 178 |
|  | &nbsp;&nbsp;&nbsp;PIMCO Total Return Fund |  |  | 2211 |
|  | &nbsp;&nbsp;&nbsp;SSGA Russell Small/Mid Cap Index Fund |  |  | 4029 |
|  | &nbsp;&nbsp;&nbsp;SSGA S&P 500 Index Fund |  |  | 20151 |
|  | &nbsp;&nbsp;&nbsp;SSGA U.S. Bond Index Fund |  |  | 1661 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2020 |  |  | 3902 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2025 |  |  | 9974 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2030 |  |  | 11602 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2035 |  |  | 7492 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2040 |  |  | 7205 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2045 |  |  | 5740 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2050 |  |  | 3456 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2055 |  |  | 2097 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2060 |  |  | 780 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement 2065 |  |  | 474 |
|  | &nbsp;&nbsp;&nbsp;SSGA Target Retirement Income |  |  | 4992 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Collective trust funds |  |  | 92029 |
|  |  | Interest rates 3.25% to 8.50% | Interest rates 3.25% to 8.50% |  |
| \* | **Loans to participants** | Maturing 2025 through 2038 | Maturing 2025 through 2038 | 5803 |
|  |  |  |  | $243025 |

---

<sup>\*</sup>Represents a party-in-interest transaction.

<sup>\*\*</sup>Cost information omitted as all investments are fully participant directed.

<u>EXHIBIT INDEX</u>

---

| | |
|:---|:---|
| Exhibit No. | Exhibit |
| [23.1](tm2518166d1_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.](tm2518166d1_ex23-1.htm) |
| [23.2](tm2518166d1_ex23-2.htm) | [Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).](tm2518166d1_ex23-2.htm) |

---

<u>SIGNATURE</u>

*The Plan*. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

---

| | | | |
|:---|:---|:---|:---|
| Date: | June 20, 2025 | By: | /s/ Sean J. Treacy |
|  |  |  | Sean J. Treacy |
|  |  |  | Plan Administrator |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated June 20, 2025, with respect to the financial statements and supplemental information included in the Annual Report of Abbott Laboratories Stock Retirement Plan on Form 11-K for the year ended December 31, 2024. We consent to the incorporation by reference of said report in the Registration Statement of Abbott Laboratories on Form S-8 (File No. 33-26685, File No. 33-504522, File No. 33-51585, File No. 33-56897, File No. 33-65127, File No. 333-19511, File No. 333-43383, File No. 333-69579, File No. 333-93257, File No. 333-74224, File No. 333-102180, File No. 333-109253, File No. 333-124849, File No. 333-141116, File No. 333-153198, File No. 333-169888, File No. 333-204772, File No. 333-227802, and File No. 333-251335).

/s/ GRANT THORNTON LLP

Chicago, Illinois<br> June 20, 2025

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated June 20, 2025, with respect to the financial statements and supplemental information included in the Annual Report of Abbott Laboratories Stock Retirement Plan (Puerto Rico) on Form 11-K for the year ended December 31, 2024. We consent to the incorporation by reference of said report in the Registration Statement of Abbott Laboratories on Form S-8 (File No. 33-26685, File No. 33-504522, File No. 33-51585, File No. 33-56897, File No. 33-65127, File No. 333-19511, File No. 333-43383, File No. 333-69579, File No. 333-93257, File No. 333-74224, File No. 333-102180, File No. 333-109253, File No. 333-124849, File No. 333-141116, File No. 333-153198, File No. 333-169888, File No. 333-204772, File No. 333-227802, and File No. 333-251335).

/s/ GRANT THORNTON LLP

Chicago, Illinois<br> June 20, 2025